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Oligonucleotide based therapeutics have been pursued in the clinic for the treatment of many
disease indications. However, unmodified oligonucleotides are polyanionic macromolecules with poor
drug-like properties. Modifications of the phosphodiester backbone provide resistance to nucleases in
vivo, making them more efficacious than unmodified nucleotides. However, these backbone
modifications have added the structural complexity of a stereogenic phosphorus center. Stereochemically
pure isomers exhibit differential efficiency dependent on its enantiopurity. The catalytic, stereocontrolled
synthesis of a phosphorus-stereogenic center is challenging, and traditionally, depends on a resolution or
use of stochiometric auxiliaries. Herein, asymmetric nucleophilic catalysis has been investigated to
provide enantio-enriched phosphonates using phosphoramidite or H-phosphonate approaches. Both
investigations utilized commercially available chiral catalysts with the enantioselectivity determined by
HPLC on a chiral stationary phase. The requisite starting materials, phosphoramidite and H-phosphonates,
have been prepared in racemic form with a variety of alcohol substituents. Chiral phosphonate products
were synthesized in acceptable yield (33%-92%) and modest enantioselectivity (up to 62% ee) after
identification of an appropriate chiral catalyst and optimization of the solvent, base, temperature,
and stoichiometric additives. The potential applications of these approaches will be discussed in the
context of catalysis and biotechnology. Following our interest in phosphorus nuclear magnetic resonance
spectroscopy (31P NMR), quantitative analysis of phosphorus abundance in environmental samples was

conducted. To prepare samples for NMR analysis pre- and post-treatment, extraction, dissolution, and pH
adjustment were performed. Quantitatively accurate 31P NMR were acquired by optimizing delay time, proton
decoupling parameters, and acquisition time.

DEDICATION
I dedicate this body of work to my beloved father who encouraged and supported me always and
showed me what an ideal father should be like. I also dedicate this to my mother and my family who have
stood beside me always. I could not have finished without their love. I also dedicate this to Claudia, who
has shown me the meaning of true love.

iii

ACKNOWLEDGEMENTS
I would like to express my gratitude to my advisor and mentor, Dr. Matthew Brichacek, for his
unwavering support, guidance, advice, patience, and encouragement throughout my PhD program. I
appreciate the time we have had together.
I would like to thank my advisory committee: Dr. Alice Bruce, Dr. Mitchell Bruce, Dr. William Gramlich,
and Dr. Michael Kienzler for their guidance, advice, and suggestions throughout my PhD work. This work
could not have been completed without the help of David LaBrecque with the instruments. I am grateful
to all the current and previous members of Brichacek group, specifically Billy, Sudeera, Elain, Saad, and
Robin.
I would like to thank Dr. Aria Amirbahman and his student, Bailey, for collaborating with me on my fourth
chapter. I could not have finished my research without their hard work collecting and preparing samples
from Highland Lake in Maine.
I extend my thanks to my family, my parents, my brothers and sisters, who have believed in me and
supported me throughout my entire journey. I also thank Claudia for her constant support and
encouragement. I love all of you.
I am grateful for my sponsor, Higher Committee for Education Development in Iraq (HECD), who has
allowed me this opportunity and has supported my scholarship.

iv

TABLE OF CONTENTS
DEDICATION .................................................................................................................................................. v
ACKNOWLEDGEMENTS ................................................................................................................................ vi
LIST OF TABLES ..............................................................................................................................................xi
LIST OF SCHEMES .........................................................................................................................................xii
LIST OF FIGURES .......................................................................................................................................... xiii
INTRODUCTION ............................................................................................................................................. 1
1.1

RNA-Based Therapeutics............................................................................................................... 1

1.1.1

Drug discovery ...................................................................................................................... 1

1.1.2

RNA based approaches ......................................................................................................... 2

1.1.3

Approved Oligonucleotide therapeutics ............................................................................... 5

1.1.4

Medical Chemistry of Oligonucleotides ................................................................................ 6

1.1.5

Chirality of Phosphodiester backbone .................................................................................. 9

1.2

Asymmetric synthesis ................................................................................................................. 11

1.2.1
1.3

Asymmetric Reaction pathways.......................................................................................... 11

Asymmetric phosphate mimics................................................................................................... 15

1.3.1

Diastereomeric separation by chromatography ................................................................. 15

1.3.2

Enzymatic enantioselective synthesis ................................................................................. 16

1.3.3

Utilizing the chirality of ribose ............................................................................................ 17

1.3.4

Utilizing chiral auxiliary ....................................................................................................... 18

1.3.5

Utilizing a chiral activator.................................................................................................... 20

v

1.4
2

Thesis Overview .......................................................................................................................... 21

ASYMMETRIC SYNTHESIS OF STEREOGENIC PHOSPHORUS P(V) CENTERS USING CHIRAL

NUCLEOPHILIC CATALYSIS........................................................................................................................... 24

3

2.1

Introduction ................................................................................................................................ 24

2.2

Results and discussion ................................................................................................................ 27

2.3

Conclusion ................................................................................................................................... 39

2.4

Materials and Methods ............................................................................................................... 39

2.4.1

General information............................................................................................................ 39

2.4.2

Isopropyl phenyl-H- phosphinate (2-13) ............................................................................. 40

2.4.3

Ethyl Phenyl-H-phosphinate (2-35) ..................................................................................... 41

2.4.4

Methyl Phenyl-H-phosphinate (2-40) ................................................................................. 41

2.4.5

Ethyl (2-methylphenyl)-H-phosphinate (2-41) .................................................................... 42

2.4.6

Ethyl (4-methoxyphenyl)-H-phosphinate (2-42) ................................................................. 42

2.4.7

Ethyl (4-fluorophenyl)-H-phosphinate (2-43) ..................................................................... 43

2.4.8

General procedure for Isopropyl (Alkyl)- phenyl-phosphonate.......................................... 43

2.4.9

(R)-Methyl (Phenyl)-phenyl-phosphonate (2-24) ............................................................... 46

2.4.10

General procedure for synthesis Ethyl (Aryl)-phenyl-phosphonate ................................... 46

ENANTIOSELECTIVE PHOSPHORYLATION OF ALCOHOLS USING PHOSPHORAMIDITES P(III) ............. 49
3.1

Introduction ................................................................................................................................ 49

3.2

Results and Discussion ................................................................................................................ 52

3.3

Catalyst Development ................................................................................................................. 60
vi

3.4

Conclusion and future direction ................................................................................................. 62

3.5

Materials and Methods ............................................................................................................... 63

3.5.1

General information............................................................................................................ 63

3.5.2

Benzyloxy bis (N,N-diisopropyl)phosphordiamide (3-9) ..................................................... 64

3.5.3

Benzyloxy Cyclohexanol N,N-diisopropylphosphoramidite (3-11) ..................................... 65

3.5.4

General procedure for asymmetric phosphitylation .......................................................... 66

3.5.5

Synthesis (S)-5-(1-Boc-Pyrolidin-2-yl)1H-tetrazole (3-16)................................................... 67

3.5.6

1H-Benzimidazole, 2-[(1S)-1-[[(1,1-dimethylethyl) dimethylsilyl]oxy]ethyl] (3-17) ........... 67

3.5.7

Synthesis 6,7-dihydro-5H-pyrrolo[1,2-a] imidazole-7-ol (3-30) .......................................... 68

3.5.8

Resolution of 6,7-dihydro-5H-pyrrolo[1,2-a] imidazole-7-ol (3-30) ................................... 68

3.5.9

Enantiomeric excess evolution from resolution ................................................................. 69

3.5.10

Synthesis rac-formyl [2,2]paracyclophane (3-21) ............................................................... 69

3.5.11

Resolution of (3-21) ............................................................................................................ 70

3.5.12

Synthesis nitrile-[2,2]paracyclophane (3-23) ...................................................................... 71

3.5.13

Synthesis 1H-tetrazle [2,2] paracyclophane (3-24) ............................................................. 71

3.5.14

(rac)-4-Bromo[2,2]paracyclophane (3-25) .......................................................................... 72

3.5.15

[2,2]paracyclophayl-4-boronic acid pinacol ester (3-26) .................................................... 73

3.5.16

[2,2]paracyclophayl-4-boronic acid (3-27) ......................................................................... 74

3.5.17

(S)-Methylbenzyl-1H-tetrazole (3-28) ................................................................................. 74

3.5.18

(S)-Methylbenzyl-5-bromo-1H-tetrazole (3-29).................................................................. 75

vii

4

QUANTITATIVE ANALYSIS OF PHOSPHORUS IN ENIROMENTAL SAMPLES BY 31P NUCLEAR MAGNETIC

RESONANCE SPECTROSCOPY ...................................................................................................................... 76
4.1

Introduction ................................................................................................................................ 76

4.2

Materials and Methods ............................................................................................................... 80

4.2.1

The sediment extraction procedure ................................................................................... 80

4.2.2

31

4.2.3

31

P NMR Acquisition Parameters ........................................................................................ 80
P NMR Processing ............................................................................................................. 81

4.3

Result and discussion .................................................................................................................. 81

4.4

Conclusion ................................................................................................................................... 86

REFERNCES .................................................................................................................................................. 87
APPENDIX A: NMR Data for Chapter 2 ..................................................................................................... 100
APPENDIX C: HPLC Chromatograms for Chapter 2 ................................................................................... 127
APPENDIX D: NMR Data for Chapter 3 ...................................................................................................... 131
APPENDIX E: HPLC spectra for Chapter 3.................................................................................................. 145
APPENDIX F: NMR Data for Chapter 4 ..................................................................................................... 147
APPENDIX G: Copyright permission from authors and publishers .......................................................... 151
BIBLIOGRAPHY .......................................................................................................................................... 155

viii

LIST OF TABLES
Table 1.1 FDA approved oligonucleotide therapeutics................................................................................. 5
Table 1.2 MipomersenTM and its stereocontrolled isomer ......................................................................... 10
Table 2.1 Base effects on the reaction conditions …………………………………………………………………………………30
Table 2.2 Effect of solvent and temperature on the phosphorylation reaction ......................................... 31
Table 2.3 Effect of electrophile on phosphorylation reaction .................................................................... 33
Table 2.4 Effect of the nucleophile on the phosphorylation reaction ........................................................ 36
Table 3.1 Effect of acid on the catalytic phosphitylation ……………….……………………………..……………………...57
Table 3.2 Effect of the solvent and the temperature on the phosphoramidite phosphitylation ............... 58
Table 4.1 Organic phosphorus classes in natural sample and their common structures……...…………………77
Table 4.2 phousphourse analysis of the samples collected from Highland Lake in Maine. ....................... 83
Table 4.3 Measurement uncertainties associated with samples using 31P NMR. ...................................... 83
Table F.1 Calculated relative error (%) for replicate integration of 31P NMR for samples……………………..164

ix

LIST OF SCHEMES
Scheme 1.1 Synthesis diastereomerically pure chiral P-center .................................................................. 15
Scheme 1.2 Phosphorothioate, phosphoroselenoate, methylphosphonate and boranophosphate have
been synthesized using α-P-modified nucleoside 5’triphosphates. ........................................................... 16
Scheme 1.3 Stereoselective synthesis of chiral auxiliare (1-9) as a precursor for stereospecific synthesis
of compound (1-14). ................................................................................................................................... 19
Scheme 1.4 Dynamic kinetic asymmetric transformation approach to the Pro TideTM synthesis.............. 21
Scheme 1.5 Overview of the thesis............................................................................................................. 22
Scheme 2.1 Synthetic approaches towards of P-stereogenic organophosphorus compounds ………..…….25
Scheme 2.2 Nucleophilic catalysts investigated . ....................................................................................... 28
Scheme 2.3 Proposed asymmetric phosphorylation mechanism............................................................... 38
Scheme 3.1 Coupling step in phosphoramidite approach of oligonucleotide synthesis……………….…………49
Scheme 3.2 Synthetic approaches of P(III)-stereogenic organophosphorus compounds .......................... 51
Scheme 3.3 Alcohol phosphitylation utilizing phosphoramidite followed by oxidation. .......................... 53
Scheme 3.4 Catalyst screening for asymmetric alcohol phosphitylation ................................................... 55
Scheme 3.5 Proposed mechanism of alcohol phosphitylation with phosphoramidites ............................ 59
Scheme 3.6 Reaction sequence to produce 1H-tetrazole [2,2]paracyclophane (3-24) ............................. 60
Scheme 3.6 Alternative reaction sequence to produce 1H-tetrazole [2,2]paracyclophane (3-24) ........... 62
Scheme 4.1 Schematic diagram of inorganic phosphorus cycling in Maine lake sediment.…………….………76

x

LIST OF FIGURES
Figure 1.1 Mechanism of protein inhibition.. ............................................................................................... 2
Figure 1.2 Three different oligonucleotide mechanisms depicted for approved antisense oligonucleotides
(ASOs) ........................................................................................................................................................... 3
Figure 1.3 Evolution of antisennse oligonuclotide therapeutics and their chemical modifications ............ 6
Figure 1.4 SPINRAZATM; FDA-approved for treatment spinal muscular atrophy .......................................... 8
Figure 1.5 Approaches for synthesis enantioenriched compounds ........................................................... 12
Figure 1.6 Energy diagram for dynamic kinetic resolution of a racemic sample ........................................ 14
Figure 1.7 Phosphatidylinositol-specific phospholipase catalyzes the P-O bond formation. ..................... 17
Figure 1.8 The stereoselective synthesis of PS-dinucleotide ...................................................................... 18
Figure 1.9 Nucleoside-3’-oxazaphospholidine monomers applied as chiral auxiliaries. ............................ 20
Figure 2.1 Structure of asymmetric phosphate mimics ……………………………………………………………………..….24
Figure 2.2 HPLC chromotogram of racemic and chiral phosphnate analogues (2-25) ............................... 34
Figure 2.3 Structural analysis of asymmetric catalyst 2-16 ........................................................................ 37
Figure 3.1 Trivalent phosphorus structures………………..………………………………………………………………………….49
Figure 3.2 HPLC chromotogram of racemic 3-15.. ...................................................................................... 53
Figure 3.3 HPLC chromotogram of 3-21...................................................................................................... 60
Figure 4.1 The 31P NMR spectrum for forest floor sample after extracted with NaOH-EDTA………………….78
Figure 4.2 T1 measured diagram. ................................................................................................................ 81
Figure 4.3 31P NMR spectrum of sample 1 at 33.7 cm sedmint depth of Highland Lake in Maine............. 84
xi

Figure A.1 1H NMR of compound 2-13 ........................................................................................................ 98
Figure A.2 13C NMR of compound 2-13 ....................................................................................................... 98
Figure A.3 31P NMR of compound 2-13 ....................................................................................................... 99
Figure A.4 1H NMR of compound 2-35 ........................................................................................................ 99
Figure A.5 13C NMR of compound 2-35 ..................................................................................................... 100
Figure A.6 31P NMR of compound 2-35 ..................................................................................................... 100
Figure A.7 1H NMR of compound 2-40 ...................................................................................................... 101
Figure A.8 13C NMR of compound 2-40 ..................................................................................................... 101
Figure A.9 31P NMR of compound 2-35 ..................................................................................................... 102
Figure A.10 1H NMR of compound 2-41 .................................................................................................... 102
Figure A.11 13C NMR of compound 2-41 ................................................................................................... 103
Figure A.12

31

P NMR of compound 2-41 .................................................................................................. 103

Figure A.13 1H NMR of compound 2-42 .................................................................................................... 104
Figure A.14 13C NMR of compound 2-42 ................................................................................................... 104
Figure A.15 31P NMR of compound 2-42 ................................................................................................... 105
Figure A.16 1H NMR of compound 2-43 .................................................................................................... 105
Figure A.17 13C NMR of compound 2-43 ................................................................................................... 106
Figure A.18 31P NMR of compound 2-43 ................................................................................................... 106
Figure A.19 1H NMR of compound 2-15 .................................................................................................... 107
Figure A.20 13C NMR of compound 2-15 ................................................................................................... 107
xii

Figure A.21 31P NMR of compound 2-15 ................................................................................................... 108
Figure A.22 1H NMR of compound 2-24 .................................................................................................... 108
Figure A.23 13C NMR of compound 2-24 ................................................................................................... 109
Figure A.24 31P NMR of compound 2-24 ................................................................................................... 109
Figure A.25 1H NMR of compound 2-25 .................................................................................................... 110
Figure A.26 13C NMR of compound 2-25 ................................................................................................... 110
Figure A.27 31P NMR of compound 2-25 ................................................................................................... 111
Figure A.28 1H NMR of compound 2-26 .................................................................................................... 111
Figure A.29 13C NMR of compound 2-26 ................................................................................................... 112
Figure A.30 31P NMR of compound 2-26 ................................................................................................... 114
Figure A.31 1H NMR of compound 2-27 .................................................................................................... 115
Figure A.32 13C NMR of compound 2-27 ................................................................................................... 113
Figure A.33 31P NMR of compound 2-27 ................................................................................................... 114
Figure A.34 1H NMR of compound 2-28 .................................................................................................... 114
Figure A.35 13C NMR of compound 2-28 ................................................................................................... 115
Figure A.36 31P NMR of compound 2-28 ................................................................................................... 115
Figure A.37 1H NMR of compound 2-31 .................................................................................................... 116
Figure A.38 13C NMR of compound 2-31 ................................................................................................... 116
Figure A.39 31P NMR of compound 2-31 ................................................................................................... 117
Figure A.40 1H NMR of compound 2-32 .................................................................................................... 117
xiii

Figure A.41 13C NMR of compound 2-32 ................................................................................................... 118
Figure A.42 31P NMR of compound 2-32 ................................................................................................... 118
Figure A.43 1H NMR of compound 2-33 .................................................................................................... 119
Figure A.44 13C NMR of compound 2-33 ................................................................................................... 119
Figure A.45 31P NMR of compound 2-33 ................................................................................................... 120
Figure A.46 1H NMR of compound 2-34 .................................................................................................... 122
Figure A.47 13C NMR of compound 2-34 ................................................................................................... 123
Figure A.48 31P NMR of compound 2-34 ................................................................................................... 123
Figure B.1 Mass spectrum for compound 2 26……………………………………………………………..……………………..122
Figure B.2 Mass spectrum for compound 2-26......................................................................................... 122
Figure B.3 Mass spectrumfor compound 2-28 ......................................................................................... 123
Figure B.4 Mass spectrum for compound 2-31......................................................................................... 123
Figure B.5 Mass spectrum for compound 2-32......................................................................................... 124
Figure B.6 Mass spectrum for compound 2-33......................................................................................... 124
Figure C.1 HPLC chromatogram of racemic 2-15 ...................................................................................... 125
Figure C.2 HPLC chromatogram of 2-15.................................................................................................... 125
Figure C.3 HPLC chromatogram of 2-24.................................................................................................... 125
Figure C.4 HPLC chromatogram of 2-25.................................................................................................... 126
Figure C.5 HPLC chromatogram of 2-26.................................................................................................... 126
Figure C.6 HPLC chromatogram of 2-27.................................................................................................... 126
xiv

Figure C.7 HPLC chromatogram of 2-28.................................................................................................... 126
Figure C.8 HPLC chromatogram of 2-31 using (S)-2-16............................................................................ 127
Figure C.9 HPLC chromatogram of 2-31 using (R)-2-16 ............................................................................ 127
Figure C.10 HPLC chromatogram of 2-32 using (S)-2-16........................................................................... 127
Figure C.11 HPLC chromatogram of 2-32 using (R)-2-16 .......................................................................... 127
Figure C.12 HPLC chromatogram of 2-33 using (R)-2-16 .......................................................................... 128
Figure C.13 HPLC chromatogram of 2-34 using (S)-2-16........................................................................... 128
Figure D.1 1H NMR of compound 3-9 ........................................................................................................ 129
Figure D.2 31P NMR of compound 3-9....................................................................................................... 129
Figure D.3 1H NMR of compound 3-11 ...................................................................................................... 130
Figure D.4 31P NMR of compound 3-11..................................................................................................... 130
Figure D.5 1H NMR of compound 3-14 ...................................................................................................... 131
Figure D.6 31P NMR of compound 3-14 ..................................................................................................... 131
Figure D.7 1H NMR of compound 3-15 ...................................................................................................... 132
Figure D.8 31P NMR of compound 3-15 ..................................................................................................... 132
Figure D.9 1H NMR of compound 3-16 ...................................................................................................... 133
Figure D.10 1H NMR of compound 3-17 .................................................................................................... 133
Figure D.11 1H NMR of compound 3-30 .................................................................................................... 134
Figure D.12 1H NMR of compound 3-20 ................................................................................................... 134
Figure D.13 1H NMR of compound 3-21 .................................................................................................... 135
xv

Figure D.14 13C NMR of compound 3-21................................................................................................... 135
Figure D.15 1H NMR of compound 3-23 .................................................................................................... 136
Figure D.16 13C NMR of compound 3-23................................................................................................... 136
Figure D.17 1H NMR of compound 3-24 .................................................................................................... 137
Figure D.18 13C NMR of compound 3-24................................................................................................... 137
Figure D.19 1H NMR of compound 3-25 .................................................................................................... 138
Figure D.20 13C NMR of compound 3-25................................................................................................... 138
Figure D.21 1H NMR of compound 3-26 .................................................................................................... 139
Figure D.22 13C NMR of compound 3-26................................................................................................... 139
Figure D.23 1H NMR of compound 3-26 .................................................................................................... 140
Figure D.24 13C NMR of compound 3-27................................................................................................... 140
Figure D.25 1H NMR of compound 3-28 .................................................................................................... 141
Figure D.26 13C NMR of compound 3-28................................................................................................... 141
Figure D.27 1H NMR of compound 3-29 .................................................................................................... 142
Figure D.28 13C NMR of compound 3-29................................................................................................... 142
Figure E.1 HPLC chromatogram of 3-15 using 5 mol % of (S)-3-16…………………………………………..…………..143
Figure E.2 HPLC chromatogram of 3-15 using 5 mol % of (S)-3-18 ........................................................... 143
Figure E.3 HPLC chromatogram of racemic trace 3-30 ............................................................................. 143
Figure E.4 HPLC chromatogram of enantioenriched compound 3-30 after enzymatic resolution .......... 144
Figure E.5 HPLC chromatogram of compound 3-24 ................................................................................. 144
xvi

Figure F.1 Representative 31P NMR spectra of extracted surficial sediment in 25.1 cm depth………………145
Figure F.2 Representative 31P NMR spectra of extracted surficial sediment in 20.2 cm dept ................. 146
Figure F.3 Representative 31P NMR spectra of extracted surficial sediment in 20.2 cm depth. ............. 146
Figure F.4 Representative 31P NMR spectra of extracted surficial sediment in 33.71 cm dept .............. 147
Figure F.5 Representative 31P NMR spectra of extracted surficial sediment in 26.3 cm dept ................ 147
Figure F.6 Representative 31P NMR spectra of extracted surficial sediment in 19 cm dept. .................. 148

xvii

CHAPTER 1

INTRODUCTION

1.1

1.1.1

RNA-Based Therapeutics

Drug discovery
After the primary sequence of the human genome was completed in 2001, the number of protein-

coding regions in the human genome was identified to be 20,000-25,000. Of all the proteins in the human
genome only around 3,000 were predicted to be suitable drug targets.1 Most currently marketed
medications have a non-covalent interaction with a particular proteins. Consequently, these drugs can
have off-target interactions and produce side effects through unexpected pathways.2 Therefore, ongoing
research in academia and pharmaceutical industry is developing therapeutic drugs with improved
selectivity and efficacy.
Proteins have multiple roles which include functioning as hormones, enzymes, ion-channels, cell
membranes, and cell receptors.1 Proteins are synthesized in a two-step process within the cell. Firstly, the
transcription step takes place when the genetic information of DNA is converted into a single strand of
messenger ribonucleic acid (mRNA) in the nucleus. After the mRNA translocates to the cytoplasm, then
translation can occur. The codons contained in mRNA dictate the structure and sequence of the protein
produced by the ribosome. Therefore, the primary function of mRNA is to transfer information from DNA
into the proteins of given cells.3 Although not as common as directly targeting proteins, blocking protein
production by targeting RNA is a viable therapeutic strategy as seen in Figure 1.1.4 For example, cytotoxic
therapeutic agents interact directly with DNA and aminoglycosides binds to bacterial ribosomal RNAs.5

1

Figure 1.1 Mechanism of protein inhibition. A) Traditional approach to drug discovery where a small
molecule directly binds to the protein of interest. B) An antisense oligonucleotide approach to drug
discovery where translation is blocked by a therapeutic oligonucleotide. Reprinted from ref.3 with
permission from Elsevier.

1.1.2

RNA based approaches

RNAs possess diverse roles in cellular processes that range from disrupting DNA and protein
interaction, suppressing genetic functions, silencing other RNA, and aiding in cellular metabolism.6 RNAbased therapies are widely utilized in the pharmaceutical industry.6 Most of these therapies are
categorized into three approaches: nucleic acid-targeting through either DNA or RNA, protein targeting,
and protein-encoding.
Oligonucleotide binds to their RNA target by Watson-Crick base pairing with high selectivity and
affinity. Oligonucleotide therapies seek to mimic enzymatic mechanisms.7 This includes antisense
oligonucleotides (ASO), short interference RNA (siRNA), microRNA (miRNA), ribozymes, and aptamers.
These therapeutics can either exploit degradation pathways or modulate RNA splicing by blocking
ribosomal machinery as seen in Figure 1.2. 5,6,8–11
2

Figure 1.2 Three different oligonucleotide mechanisms depicted for approved antisense oligonucleotides
(ASOs) and siRNA (a) Gamper ASO, ASO with a central gap of DNA, interacts with target mRNA in the
nucleus. Then, RNase-H1 recognizes the DNA-RNA heteroduplex complex and cleaves the complementary
RNA strand and leaves the ASO strand intact to bind to another target. (b) A duplex siRNA interacts with
other proteins to form the RISC complex which contains the antisense strand and the protein Ago2. The
Ago2-RISC complex helps the antisense strand to bind to the target mRNA and selectively degrades the
target RNA while leaving the antisense strand intact. (c) A modified ASO sterically blocks and alters the
mRNA splicing process in the nucleus. ASO, antisense oligonucleotide; mRNA, messenger RNA; siRNA,
short interference RNA; Ago2, argonaute-2; RISC, RNA-induced silencing complex.12

3

The most direct strategy of targeting RNA is to bind to RNA with single stranded antisense
oligonucleotides (ASOs).13

ASOs are short (12-24) synthetic nucleotides in length that bind to

complementary mRNA through Watson-Crick base pairing, and modulate the function of the targeted
mRNA. The ASOs can act on a precursor mRNA (pre-mRNA) in the nucleus and modulate its function by
promoting endogenous RNase-H1 degradation as seen in Figure 1.2a. RNase-H1 is utilized to degrade RNADNA heteroduplexes that are formed followed by the synthetic ASO being released to target additional
pre-mRNA.12 ASOs do not include oligonucleotides that form triple helix structure with DNA, or
oligonucleotides that bind to proteins.14
Utilizing short interference RNA (siRNA) is another method of targeting RNA that induces enzymatic
degradation of the target RNA. In this process, Argonaute 2 (Ago2) is responsible for the cleavage of the
target RNA by an RNase-H like mechanism as seen in Figure 1.2b.12 First, a single stranded siRNA binds to
the target RNA and subsequently to Ago2 and other unknown factors to form the RNA-induced silencing
complex (RISC complex).12,14 RISC facilitates cleavage of the RNA at a specific site followed by release of
the intact siRNA to target additional RNA as seen in Figure 1.2b. 12,14
A final method of action for oligonucleotide therapeutics works by blocking modification of the mRNA
during the maturation process. This process can either be disrupting the interaction between the target
RNA and essential ribosomal subunits or modulating the splicing process to arrest protein translation as
seen in Figure 1.2c.12 Before forming a mature mRNA, a pre-mRNA is enzymatically modified and spliced
resulting in multiple isoforms.8 Thus, modified ASOs are usually designed to avoid the enzymatic
degradation by RNase-H or Ago2. For example, EteplirsenTM is a morpholino modification that was
approved by the FDA to treat Duchene muscular dystrophy (DMD) in 2016.15 EteplirsenTM disrupts the
splicing of pre-mRNA that is necessary for DMD to occur, therefore decreasing the production of
dystrophin lacking exon 51.16
4

1.1.3

Approved Oligonucleotide therapeutics
Oligonucleotide therapies represent a promising platform that has the ability to selectively target

RNAs in the cell. In this strategy nucleic acids indirectly block protein production and therefore have the
potential to produce many therapeutic.14 For example, preliminary work has done by Zamecnik et al. in
1977 that shows the inhibition of Rous sarcoma virus by targeting 13 nucleotides of a viral RNA
sequence.17

Furthermore, over the last decade the FDA has approved multiple oligonucleotide

therapeutics for the treatment of various diseases indication as seen in Table 1.1.7,18
Table 1.1 FDA approved oligonucleotide therapeutics7

Drug name

Indication

Company

Type

KynamroTM
(mipomersen sodium)
DefitelioTM
(defibrotide sodium)

Homozygous Familial
Hypercholesterolemia
Hepatic Veno
Occlusive Disease

Antisense Oligonucleotide

Exondys 51TM
(eteplirsen)
Spinraza (nusinersen)

Duchenne Muscular
Dystrophy
Spinal Muscular
Atrophy
Hepatitis B

Kastle
Therapeutics LLC
Jazz
Pharmaceuticals
Plc
Sarepta
Therapeutics
Biogen
Dynavax
Technologies

Heplisav-BTM (hepatitis
B vaccine, adjuvanted)
TegsediTM
(inotersen sodium)
Onpattro (patisiran)
GivlaariTM (givosiran)
Vyondys 53TM
(golodirsen)

Familial Amyloid
Neuropathies
Familial Amyloid
Neuropathies
Acute Hepatic
Porphyria
Duchenne Muscular
Dystrophy

Akcea
Therapeutics
Alnylam
Pharmaceuticals
Alnylam
Pharmaceuticals
Sarepta
Therapeutics
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FDA
Approval
2013

Oligonucleotide, natural
product

2016

Antisense Oligonucleotide

2016

Antisense Oligonucleotide

2016

Cytidine phosphoguanosine (CpG) oligonucleotide
as adjuvant
Antisense Oligonucleotide

2017

siRNA

2018

siRNA

2019

Antisense Oligonucleotide

2019

2018

1.1.4

Medical Chemistry of Oligonucleotides

Natural oligonucleotide are phosphodiesters, which contain three major components: phosphate,
sugar, and nucleobase as seen in Figure 1.3.14 Unmodified nucleic acids are unstable molecules in
biological systems. Specifically, they are rapidly degraded by nuclease enzymes which cleave their
phosphodiester linkages before reaching their target preventing their use as therapeutic agents.

Figure 1.3 Evolution of antisense oligonucleotide therapeutics and their chemical modifications; melting
temperature changing (ΔTm) per modification compared with corresponding RNA/DNA pairing.14
In addition to enzymatic degradation, the inefficient pharmacokinetic properties of oligonucleotide
therapeutics make them non-ideal drug candidates because they are weakly bound to plasma proteins
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and thus rapidly filtered by the kidney and excreted.6 Also, in order for the antisense oligonucleotides
(ASOs) to be an efficacious drug, they must have a high affinity for their RNA/DNA targets.6,19 Next, to
overcome poor permeation across the cell membrane, the use of chemical modifications to the
oligonucleotide structure have been utilized to enhance the drug-like properties. The desirable properties
to achieve include improving nuclease resistance, cellular uptake, target affinity, pharmacokinetic, and
base-pairing specificity.19 Modifying each of the 25 different positions of a dinucleotide subunit results in
additive effects. According to these modifications, the antisense oligonucleotides (ASOs) have been
categorized into three generations as seen in Figure 1.3.20,21
The effect of modifying ASOs is usually done by measuring the duplex or triplex melting temperature
(Tm) using UV thermal analysis. Melting temperature (Tm) is the temperature where exactly half of the
oligonucleotide molecules are single-stranded and the other half remain double-stranded. Typically, the
change of Tm per modification (ΔTm/ mod) is calculated and compared with a native duplex reference.
However, multiple sequences need to be examined to determine the binding affinity per modification for
a specific sequence.22
Modifying the nucleobase is not common because it is responsible for binding with the
complementary mRNA target with Watson-Crick base pairing.19,20 Modification of the furanose sugar can
enhance binding affinity, improve enzymatic stability, or increase plasma protein interactions thereby
preventing renal secretion. For example, phosphorodiamidate morpholino oligomers (PMO) and peptide
nucleic acids (PNA) are third generation ASOs with the most favorable properties in vitro and in vivo.
Thermal stability increases for PMO-DNA complexes are 0.4 °C/modification while PNA-RNA duplexes are
up to 1 °C/modification compared with their corresponding RNA/DNA pairing as shown in Figure 1.3.20,23,24
The phosphodiester backbone (Figure 1.3) can be chemically modified to substitute one of the nonbridging oxygen atoms for sulfur (phosphorothioate), methyl (methyl phosphonate), nitrogen
(phosphoroamidate), or boron (boranophosphate). Backbone modifications increase stability toward
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nucleases, improve solubility in water, and improve binding affinity to mRNA. Collectively, these
modifications make them more efficacious in antisense technology and more stable during automated
oligonucleotide synthesis.19–21 In vitro studies showed that methyl substitutions increased the thermal
stability in α-methyl phosphonate (MP)-DNA duplex by 1.9 °C per modification compared to the
corresponding RNA-DNA complexes.25 In contrast, the thermal stability decreased for all
phosphorothioate (PS)-DNA duplexes by 0.5 °C per modification.26
In addition to therapeutic applications, phosphorothioate oligonucleotides have been successfully
used in gene silencing and as a probe to discover the functions of internucleotide phosphates.27 Many
clinical candidates have the PS moiety. For example, SpinrazaTM is a phosphorothioate (18-mer) that was
recently approved by FDA for the treatment of a genetic condition, spinal muscular atrophy, that causes
infant death (Figure 1.4).28

Figure 1.4 SpinrazaTM: FDA approved for the treatment of spinal muscular atrophy in 2016. The structure
of a prochiral phosphodiester and the corresponding phosphorothioate moiety in SpinrazaTM containing
131,072 individual isomers.
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1.1.5

Chirality of Phosphodiester backbone

For biological activity of chiral drug is dependent on the spatial arrangement of atom in three
dimensions. When these stereoisomers interact with biological systems, metabolization may occur at
different rates or use different pathways. While one enantiomer shows activity the other enantiomer may
be non-active, affect different targets, or even be toxic.29 In order to optimize the therapeutic qualities of
chiral drugs, while avoiding unwanted effects, new approaches are needed to selectively synthesize an
enantiopure compound.
Although backbone modification of oligonucleotides improves pharmaceutical profiles, it converts an
achiral phosphodiester linkage into a chiral phosphorus center with two different stereochemical
configurations designated SP (blue) and RP (red) (Figure 1.4). Due to synthetic limitations, a mixture of both
configurations at the P-center is present in current FDA-approved ASOs. Iwamoto et al. studied the duplex
stability of stereochemically pure oligonucleotide components of MipomersenTM and several of its
stereodefined (Table 1.2).30 Furthermore, many studies have confirmed that a stereodefined center in a
single molecule can dramatically impact the pharmaceutical properties of the ASOs by affecting their
thermal stability.19,30–32
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Table 1.2 MipomersenTM and its stereocontrolled isomers
ASO

Sequence

MipomersenTM

Number of
stereoisomers
524,288

Tm
(°C)
80.2

WV-1

1

84.7

WV-2

1

74.7

WV-3

1

78.8

WV-4

1

80.0

WV-5

1

81.6

WV-6

1

78.3

WV-7

1

68.2

MipomersenTM is 20-mer oligonucleotide with phosphorothioate (PS) linkages, DNA core, and 2’MOE modified end. Due to the incorporation of PS linkages a total of 524,288 isomers are possible with
mixture having a melting temperature of 80.2 °C as in Table 1.2 (Entry 1). The Tm of the all-RP (WV-1) was
higher at 84.7 °C, whereas the Tm of the all-SP (WV-2) was 74.7 °C (Table 1.2 Entries 2 and 3). The studies
also investigated the duplex stability of nucleotides that have controlled incorporation of RP or RS linkages
at specific locations. Although no absolute rule can be formed about backbone modification, the stability
of the DNA complexes are sensitive to the stereochemical relationship at specific sites on the
oligonucleotide (Table 1.2 WV-3 through WV-7).30
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1.2

Asymmetric synthesis

1.2.1

Asymmetric Reaction pathways

Asymmetric synthesis is the reaction or reaction sequence that selectively forms one or more new
stereogenic elements. In asymmetric synthesis, achiral molecules are enantioselectivity converted into
chiral molecules. In other words, asymmetric synthesis is a method for producing enantiomerically pure
compounds by favoring one stereoisomer over.33 Stereoisomers are the molecules with the same
connectivity, but with the different arrangement in three-dimensional space.34 Asymmetric synthesis is
challenging because it takes a racemic mixture and converts it preferentially into one stereoisomer over
another (Figure 1.5).35
Since the early 1980s, asymmetric synthesis has become a powerful tool to produce enantioenriched
molecules for use in pharmaceutical applications. Generally, the formation of a new stereogenic center
on a substrate is caused by induction of a chiral group. Several types of asymmetric induction are known.36
First, internal asymmetric induction occurs when a reactive center is connected by a covalent bond to a
stereogenic center and they remain together during the reaction. Alternatively, relayed asymmetric
induction occurs when a stereogenic center is introduced temporarily and then removed in separate
chemical reaction.
Enantiopure compounds can be synthesized by covalently attaching a chiral molecule to an achiral
substrate and subsequently removing the functionality later. Chiral molecules utilized in this manner are
called chiral auxiliaries (Figure 1.5).35,37 The stereochemistry of the chiral auxiliary controls the
stereoselectivity of the asymmetric synthesis. Stoichiometric amounts of the chiral auxiliary are always
required to achieve a single enantiomer, but this process can be cost-efficient if the chiral auxiliary can be
recycled.37
11

Figure 1.5 Approaches for the synthesis of enantioenriched compounds35
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Using a chiral reagent is a widely used approach to obtaining enantioenriched substances.38
Similar to chiral auxiliaries, the selectivity of the reaction is controlled by the chirality of the reagent.
However, the chiral reagent is not covalently attached to the starting material or product of a reaction
and thus does not have to be removed in a separate synthetic step. For example, the asymmetric
hydration of an alkene utilizes a chiral borane reagent to hydroborate the alkene followed by oxidation
and hydrolysis.38 Despite the development of many chiral reagents, substrate scope and selectivity are
often limited.
Another method of obtaining enantioenriched materials is to use a resolution. In a resolution, an
equimolar mixture of enantiomers is separated using either physical or chemical approaches. The
separation of the enantiomers is possible after they have been converted into diastereomers using a chiral
reagent. Diastereomers are able to be separated due to their different physical or chemical properties.
Once separated, the chiral reagent is removed providing pure enantiomers.
As an alternative to a classic resolution, a kinetic resolution (KR) occurs when there is a large
difference between the reaction rates of the enantiomers. Typically, the unwanted enantiomer is
converted into a different molecule using a chiral reagent leaving the desired enantiomer intact (Figure
1.5). For this strategy to be successful, a selective chiral reagent is needed and there is always 50% yield
lost to the byproduct.35,39–41 Enzymes have been extensively used as reagents in kinetic resolutions.
Unlike the kinetic resolution (KR), the dynamic kinetic resolution (DKR) is a powerful approach in
asymmetric synthesis by efficiently combining the KR and racemization of the slower reacting enantiomer
(Figure 1.5).35,40,42,43 Therefore, a racemic mixture can be converted into an enantiopure compound with
a theoretical yield of 100%.
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A potential energy diagram of a DKR is shown in Figure 1.6.39,40 The (R) and (S) enantiomers of the
starting material (SM) are in rapid equilibrium. ΔGrac‡ represents activation energy associated with the
interconversion. Both enantiomers (SMS and SMR) have equal free energies and can associate with the
chiral catalyst. The enantiomers react at different rates since the transition states are diastereomeric. One
pathway has a higher transition state, in this schematic TSS, and the other is a more kinetically accessible
pathway that has a lower transition state, TSR in Figure 1.6.44 The reactivity difference of the two pathways
is designated by ΔΔG≠. The selectivity of the chiral catalyst to produce a single isomer can be correlated
to its ability to increase ΔΔG≠. As a result, controlling the reaction rates enable the stereoselective
synthesis of a chiral product from racemic starting materials.44

Figure 1.6 Energy diagram of dynamic kinetic resolution for (R and S) enantiomers, in which a catalyst
can selectively lower a transition state (TS) for one isomer leading to favorable reaction outcome.44

When considering all methods of obtaining single enantiomers, the DKR can be considered the
most effective approach to produce stereoselective products because DRKs utilize non-stochiometric
amounts of a chiral reagent, can be catalyzed, and theoretically provide 100% yield. Numerous examples
of DKRs are reported in the literature to provide pharmaceuticals and natural products.39,40,44
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1.3

Asymmetric phosphate mimics
As previously mentioned, the chemical modification of the phosphodiester backbone in

oligonucleotides enables efficacious oligonucleotide therapies.28 Substitution of either of the two nonbridging oxygen atoms of the internucleotide phosphorus creates a chiral phosphoryl center, and the
properties of these oligonucleotide analogs are affected by the chirality of the phosphorus atom.
Therefore, the stereocontrolled synthesis of chiral phosphate oligonucleotides in literature have been
pursued extensively.45,46

1.3.1

Diastereomeric separation by chromatography

The first approach to obtaining p-chiral oligonucleotide analogs was chromatographic separation of
diastereomers. A racemic mixture of a dinucleotide can be separated using high-performance liquid
chromatography (HPLC) to obtain single isomers of stereodefined phosphorus centers. The chiral
stationary phase can be used in either normal- or reverse-phase modes to separate the diastereomers.
The diastereopure product can be utilized for further chemical or biological studies. For example,
diastereopure dinucleotide analogs can be converted into the corresponding 3’-phosphoramidite
dinucleotide building blocks (1-3) which are used in the solid-phase syntheses of oligonucleotides as in
Scheme 1.1.47,48

Scheme 1.1 Synthesis of diastereomerically pure dimer building blocks with a chiral P-center.46
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Oligonucleotides with multiple stereogenic phosphorus centers can be synthesized in a nonstereocontrolled manner analogous to the synthesis of dinucleotides. However, the chromatographic
separation is not guaranteed since the target structure contains many chiral phosphorus moieties.
Furthermore, the reactivity of dimer building blocks is typically lower than monomers.47,48

1.3.2

Enzymatic enantioselective synthesis

Enzymatic synthesis of oligonucleotides can be achieved using ribo- or 2’deoxyribo-nucleoside 5’triphosphates and various enzymes including DNA polymerase I and T7 RNA polymerase. Modifying the
nucleoside 5’-triphosphate results in P-chiral oligonucleotides instead of a natural phosphodiester as
shown in Scheme 1.2. For example, α-P-thiothymidine 5’-triphosphate (1-5, X = S) was used to synthesize
fully modified phosphorothioate oligonucleosides. Unlike chromatographic-separation approaches,
stereodefined products are always achieved here. Therefore, oligonucleotides longer than 10-20 mers can
be synthesized that contain diastereomerically pure phosphorothioates, phosphoroselenoates, and
methyl-phosphonates.49–51 Mechanistic studies by Rayn et al. have shown that enzymes lower the barrier
to phosphorus-oxygen bond formation through different scenarios including nucleophilic activation by
base catalysis, leaving group activation by acid catalysis, and oxyanion hole-type stabilization of the
transition state (Figure 1.7).52,53

Scheme 1.2 Phosphorothioate, phosphoroselenoate, methylphosphonate and boranophosphate have
been synthesized using α-P-modified nucleoside 5’triphosphates.
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Figure 1.7 Phosphatidylinositol-specific phospholipase catalyzes the phosphorus-oxygen bond formation
using leaving group activation, nucleophilic activation, and pentavalent transition state stabilization as
proposed by Ryan et al.52
However, there are some limitations in enzymatic asymmetric synthesis. First, phosphate-forming
enzymes are very substrate specific and may not process P-modified nucleotide triphosphates. Second,
both enantiomers of the phosphate mimic are often not available due to enzyme specificity. For example,
only (RP)-phosphorothioate, SP-boranophosphate, and SP-methylphosphonate linkages have been
enzymatically obtained using SP-isomers of compound 1-5. Next, large-scale production of
oligonucleotides has not been achieved using enzymatic synthesis. Lastly, the oligonucleotide products
have to be purified from byproducts before subsequent chemical treatments.54

1.3.3

Utilizing the chirality of ribose

The stereocontrolled chemical synthesis of chiral phosphorus oligonucleotide analogs has also been
approached utilizing the chirality of ribose.55,56 Traditional phosphoramidite synthesis of dinucleotide
thiophosphates results in a mixture of RP and SP but isn’t equal.57 Therefore, the inherent chirality of ribose
or deoxyribose has induced an asymmetric environment for the stereoselective synthesis of P-chiral
internucleotide phosphate mimics. For example, Seio et al. have developed a 3’-phosphoramidite moiety
possessing a covalent linker with the phosphorus atom (compound 1-7).58 This tethered phosphoramidite
17

has used as a building block to synthesize dithymidine phosphorothioate. The macrocycle provides steric
hindrance around the phosphorus center, which favors one formation of one enantiomer. A high
stereoselectivity of the RP-diastereomer was obtained (RP:SP = 86:14) without using any other chiral
source.58
Despite the asymmetric environment created using the chirality of ribose, it is still challenging to
obtain higher stereoselectivity because of structural limitations. Moreover, only one of two phosphorus
isomers are obtained within this approach as a result of the chirality of ribose.54

Figure 1.8 Cyclic phosphoramidite monomer used for the stereoselective synthesis of thiophosphate
dinucleotide.

1.3.4

Utilizing chiral auxiliary

P-chiral phosphite triesters can be synthesized using P(III) or P(V)-chiral auxiliaries that are covalently
bonded to the phosphorus center as seen in Scheme 1.3.59 For example, Agrawal et al. have utilized a
prolinol moiety to promote a condensation process that utilizes oxazaphospholidine analogues.60
Specifically, P-chloro-oxazaphospholidine (1-9) was coupled with protected nucleoside 1-10 to give a
single diastereomer of 1-11 in 90% yield. Notably, both D- and L-proline can be used to obtain either
configuration of the oxazaphospholidine. The condensation of compound 1-11 with a polymer-bound
nucleoside (1-12) was facilitate by 1H-tetrazole. After sulfurization and deprotection reactions,
18

oligonucleotide phosphorothioate 1-14 was obtained with high stereoselectivity ( RP : SP = 10 : 90 to 14 :
86 ).54,60

Scheme 1.3 Stereoselective synthesis of prolinol oxazaphospholidine derivative (1-9) as a precursor for
stereospecific synthesis of compound (1-15).60
Other chiral auxiliaries have been developed for the synthesis of phosphorothioate oligonucleotides
(Figure 1.9).54 Chiral auxiliary approaches allow both RP and SP to be synthesized with excellent
diastereoselective using solid-phase phosphorothioate synthesis me.54 However, covalent attachment of
the chiral auxiliary requires additional chemical reactions and purifications to isolate the desired
dinucleotide products. Additionally, a stoichiometric amount of the chiral auxiliary is always required
because the stereoselectivity is dependent on the structure of the chiral auxiliary.54,61
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Figure 1.9 Nucleoside-3’-oxazaphospholidine monomers used as chiral auxiliaries for the
stereocontrolled synthesis of oligonucleotide phosphorothioates or phosphoroselenoates.54

1.3.5

Utilizing a chiral activator

Despite the inherent advantages of utilizing a dynamic kinetic asymmetric transformation (DYKAT) to
synthesize P-stereogenic compounds, very few reports are in the literature.53 DYKATs employ a chiral
activator to selectively transform a racemic mixture into a single stereoisomer. In most cases, a
substoichiometric amount of a chiral substance can still achieve high levels of enantioselectivity whereas
a stoichiometric amount was necessary for a chiral auxiliary or chiral reagent. DiRocco et al. has
successfully assembled biologically active prodrugs via a catalytic stereoselective approach by coupling Pchiral phosphonamidates (1-19) to nucleotides as shown in Scheme 1.4.53 Despite this success,
asymmetric synthesis of P-stereogenic compounds suffers from low catalytic turnover, low
stereoselectivity, and limited substrate scope. Therefore, no general protocol for the synthesis of chiral
phosphorus compounds has been reported and developing a method is challenging since the P(V) bond
formation mechanism is still not fully understood.62–64
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Scheme 1.4 Dynamic kinetic asymmetric transformation (DYKAT) towards the synthesis of ProTideTM
nucleotides (1-22).53

1.4

Thesis Overview
Phosphate mimics have been developed to improve RNA therapeutic properties including stability to

nuclease degradation, enhancement of binding affinity to complementary sequences, and improved cell
membrane permeability. However, these modifications have added the structural complexity of a
stereogenic phosphorus center. Stereochemically pure isomers exhibit differential activity in vitro and in
vivo dependent on its enantiopurity.30,65
The main goal of this research is to synthesize P-stereogenic phosphate mimics in a stereocontrolled
manner. Specifically, asymmetric nucleophilic catalysis has been investigated to provide enantio-enriched
phosphonates using H-phosphonate (Chapter 2) and phosphoramidite approaches (Chapter 3) as shown
in Scheme 1.5. Both approaches utilized commercially available chiral catalysts with the enantioselectivity
determined by HPLC on a chiral stationary phase. The requisite starting materials, either
phosphoramidites or H-phosphonates, have been prepared in racemic form and subsequently reacted
with a variety of alcohols.
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Scheme 1.5 Overview of the thesis
In chapter two, chiral phosphonate products were synthesized in excellent yield (up to 92%) and
modest enantioselectivity (up to 62% ee) after identification of an appropriate chiral catalyst and
optimization of the solvent, base, temperature, and stoichiometric additives. The potential applications
of these approaches could be extended to P-chiral nucleotide analogs.
In chapter three, asymmetric phosphorylation using racemic phosphoramidites P(III) was carried out
utilizing a chiral nucleophilic amine in catalytic amounts (10 mol %). Phenyl isocyanate was used during
the reaction as an amine scavenger to increase the catalyst turnover. Many conditions were tested
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involving the solvent, temperature, acid, and chiral nucleophilic catalyst. The catalyst (S)-5-(1-BocPyrolidin-2-yl)1H-tetrazole (3-16) in CH2Cl2 at a reduced temperature was found to be the most selective
conditions with enantioselectivities up to 23% and a modest phosphate yield (3-15) up to 49%. Based on
the identification of a tetrazole as a requisite structure in the nucleophilic catalyst, the synthesis of a chiral
cyclophane that contains a 1H-tetrazole moiety (3-24) was pursued to provide a novel catalyst structure.
The target tetrazole 3-24 was synthesized in racemic form using a zinc bromide catalyzed [3+2]
cycloaddition of a cyclophane nitrile with sodium azide albeit in poor yield (10%).
In chapter four, Phosphorus nuclear magnetic resonance (31P NMR) spectroscopy was used for
quantitative analysis of organic phosphorus in environmental samples. Preparation of samples for the 31P
NMR analysis, including pre- and post-treatment, extraction, and redissolving samples for the 31P NMR
experiment was conducted. To obtain quantitative data, the delay time, proton decoupling, and
experiment length needed to be optimized. Sample pH was found to significantly affect the 31P NMR
resolution.
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CHAPTER 2

2

2.1

ASYMMETRIC SYNTHESIS OF STEREOGENIC PHOSPHORUS P(V) CENTERS USING CHIRAL
NUCLEOPHILIC CATALYSIS

Introduction
Organophosphorus compounds are common motifs in nucleotides,30,49,66 pesticides,67,68

herbicides69,70 and flame retardants.71 Commonly, phosphate mimics with tri, tetra, or pentacoordinate
geometries, with unique substitutions, create a chirality center on the phosphorus atom as shown in
Figure 2.1. These compounds normally have stable configurations, but their stabilities change
corresponding to the coordination and the nature of the substitution around the phosphorus center.72
Chiral phosphate mimics have been extensively utilized in transition metal catalysts, 73 as chiral
reagents,74–76 and in coordination chemistry.77,78 Furthermore, compounds with stereogenic phosphate
centers are of great interest in biological applications.79 For example, using phosphorus-stereogenic
analogues in antisense therapy improves potency, stability against enzymatic degradation, and
bioavailability.10 However, current nucleotide therapeutics are stereoisomeric mixtures. Previous studies
have shown that nucleotide stereoisomers at phosphorus possess distinct therapeutic activities and
physical properties.30,80–82

Figure 2.1 Structure of asymmetric phosphate mimics

Despite the importance of enantiopure P-stereogenic compounds, the chemical synthesis remains
unsolved. Various strategies have been pursued using either P-O, P-N, or P-C bond formation to create a
stereogenic center.72 Traditionally, P-stereogenic centers have been synthesized using multi-step
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approaches involving the transfer of achiral or prochiral phosphorus groups to chiral-pool amines and
alcohols as seen in Scheme 2.1a. However, the desymmetrization of prochiral substrates is limited by
substrate scope and modest stereoselectivity. 83

Scheme 2.1 Synthetic approaches towards P-stereogenic organophosphorus compounds. a) desymmerization
of prochiral phosphorus substrate, b) P-stereogenic organophosphoryl compounds from enantiopure HPhosphinates, c) Using a chiral auxiliary or promotor for P-stereogenic organophosphorus synthesis, d)
Catalytic asymmetric synthesis, e) Asymmetric phosphorylation via chiral nucleophilic catalyst.
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Another approach to chiral phosphorus centers involves the transformation of non-racemic Hphosphinates (2-3) to corresponding P-stereogenic compounds (2-4) through dehydrogenative coupling
known as the Atherton-Todd reactions (Scheme 2.1b). Although H-Phosphonates cleanly transfer the
stereochemistry to the product, construction of the enantiopure substrate often requires multiple
synthetic steps.84 Alternatively, a racemic phosphorus center can be coupled with a chiral auxiliary or
promotor as shown Scheme 2.1c. However, the stoichiometric amount of chiral auxiliary is always
required to achieve high stereoselectivity in the products. Moreover, a chiral auxiliary is covalently bonded
to the product, necessitating subsequent chemical reactions and purifications to remove it from the
desired product.85
In 2010, Jordan et al. synthesized a phosphate moiety through a highly-selective kinetic resolution
using a chiral, peptide-based phosphorylation catalyst.86 The chiral peptide was able to efficiently mimic
enzymatic catalysts that phosphorylate nucleotides using nucleophilic activation, leaving group activation,
and oxyanion-hole transition state stabilization.87,88 However, this approach is limited in scope because
each peptide is optimized for a single substrate. Based on this work, DiRoco et al. designed a general chiral
nucleophilic catalyst for the synthesis of enantiopure prodrugs via a dynamic kinetic asymmetric
transformation (DKAT) as seen in Scheme 2.1d.53 The prodrug moiety contains an amino acid that makes
hydrogen bonds to the nucleophilic catalyst to stabilize the transition state. Therefore, DiRoco’s catalyst
is limited to phosphates with amino acid substituents.53 Other approaches to produce P-stereogenic
compounds, that are not shown in scheme 2.1, include chiral-stationary phase separation and resolution
using physical properties.47,54,72,89,90
To overcome the synthetic limitations found in the synthesis of P-stereogenic phosphate mimics,
a DKAT utilizing a chiral nucleophilic catalyst was pursued (Scheme 2.1e). A racemic H-phosphinate moiety
(2-11) can be coupled to nucleophilic alcohols under halogenation conditions to produce chiral
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phosphonate products as shown in Scheme 2.1e. This general approach would utilize a catalytic amount
of a chiral substance and a wide range of racemic phosphorus substrates could be used including
nucleotides or prodrug structures.

2.2

Results and discussion
H-Phosphinates and phosphonate are useful precursors to a wide range of P-stereogenic

compounds.

91–93

Therefore, racemic H-Phosphinate 2-13 was an ideal substrate to investigate the

proposed DKAT using chiral nucleophilic catalysts. To obtain substrate 2-13, esterification of phenyl
phosphinic acid in neat isopropanol at an elevated temperature (138 °C) provides the product in 70% yield.
Coupling of H-Phosphinate 2-13 with phenol (2-14) under halogenation conditions (CCl4, 4 equiv.) provides
the phosphonate product (2-15) in 76% yield. Stoichiometric amounts of N,N-diisopropylethyl amine are
included to consume the HCl byproduct of the halogenation product.
Using the optimized conditions for the racemic formation of 2-15, a wide a variety of chiral
nucleophilic catalysts were screened to quantify the enantiomeric enrichment of the phosphorus center
(Scheme 2.2). Using the catalyst developed by DiRoco et al. (2-18 and 2-19) minimal stereoselectivity (-9%
ee and 8% ee respectively) was observed.53 The suboptimal enantioselectivities are likely due to the
remote chiral site being unable to effectively induce asymmetry in substrates that do not possess a Hbonding functionality. Planar-chiral catalyst 2-20, known as Fu’s catalyst, is a ferrocene analogue of 4diethylaminopyridine (DMAP) with high nucleophilicity and low steric hindrance at the nucleophilic
nitrogen atom.94 The product 2-15 was obtained with an improved selectivity of 34% ee and a moderate
yield of 45%. Alternative heterocyclic nucleophilic catalysts 2-21 and 2-22 provide similar
enantioselectivities (-24% and 11% ee) and chemical yields (38% and 42%). Chiral thiourea 2-23, which
does not operate as a nucleophilic catalyst, does not induce significant levels of stereoselectivity (10% ee)
while resulting in a dramatically diminished yield of 14%. Despite limited success with common
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nucleophilic catalysts, the results demonstrate the enantiomeric enrichment was significantly impacted
by catalyst structure.

Conditions: 2-13 (1 equiv.), CCl4 (4 equiv.), PhOH (0.5 equiv.) i-Pr2NEt (2 equiv.), Cat. 20 mol %, CH2Cl2 (0.1 M
solution), 7 h; Enantiomeric excess (ee) was determined by HPLC analysis; a catalyst 10 mol %; b catalyst 50
mol %.
Scheme 2.2 Nucleophilic catalysts investigated. Yield and enantiomeric excess of isolated products are given.

Benzotetramisole (BTM, 2-16) was originally developed by Briman et al for the kinetic resolution
of alcohols and is now commercially available.95–97 BTM was tested in the standard H-Phosphinate
coupling of 2-13 and 2-14 under halogenation conditions and was found to produce the highest levels of
enantioselectivity. Specifically, 20 mol % of (S)-BTM produced phosphonate 2-15 in 58% yield and 49% ee
(Scheme 2.2). Increasing the catalyst loading from 10 mol % to 20 mol % to 50 mol % resulted in small
increases in enantioselectivity of 46%, 49%, and 54% ee respectively. Structurally similar Tetramisole (228

17) is a capable catalyst providing 2-15 in 45% yield and 44% ee. Mechanistically, we envisioned the
nucleophilic BTM catalyst becoming covalently bonded to the phosphoryl center while facilitating
racemization to produce the observed enantioenrichment. Consequently, BTM was identified as the
optimal catalyst for the DKAT of racemic H-phosphinates into chiral phosphonates.
In order to optimize the yield and enantioselectivity of 2-15, the effect of the base was
investigated and results are shown in Table 2.1. As established in the catalyst screen, N,Ndiisopropylethylamine (DIPEA) has the highest enantioselectivity (49% ee) and a respectable yield of 58%
(Table 2.1, Entry 7). Among the investigated bases, potassium tert-butoxide (KOtBu) provided the highest
chemical yield of 63%, but with near-complete loss of enantioselectivity (7% ee). Non-nucleophilic amine
bases, including DBU, ABCO and DABCO, provided 2-15 with diminished enantioselectivities of 20% ee,
30% ee and 33% ee respectively. The starting material was recovered and no product was observed when
using hindered bases such as proton sponge (1,8-bis(dimethylamino)naphthalene) or di-tert-butyl
pyridine (Table 2.1 Entries 5 and 6). All other reactions showed complete consumption of H-phosphine
starting material and no ongoing product formation as judged by 31P NMR.
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Table 2.1 Base effects on the reaction conditions.
Entrya

a

Base

pKa in DMSO*

Yield (%)b

ee (%)c

1

KOtBu

19.298

60

7

2

DBU

1298

63

20

3

ABCO

9.899

50

32

4

DABCO

2.97, 8.9399,100

15

33

5

Proton Sponge

7.50100

0

---

6

DTBP

0.81101

0

---

7

DIPEA

998

58

49

Conditions: 2-13 (1 equiv.), CCl4 (4 equiv.), PhOH (1 equiv.), Base (2 equiv.), 2-16 (20 mol %), CH2Cl2 (0.1 M

solution), 7 h; bYields were determined by HPLC analysis; cee values were determined by HPLC analysis. KOtBu,
Potassium tert-butoxide; DBU, 1,8-Diazabicyclo [5.4.0] undec-7-ene; ABCO, Quinuclidine; DABCO, 1,4diazabicyclo[2.2.2]octane; Proton Sponge, 1,8-Bis(dimethylamino)naphthalene; DTBP, Di-tert-butyl pyridine;
DIPEA, N,N-diisopropylethylamine.* pKa was shown for conjugate acid.

After identifying N,N-diisopropylethylamine as the optimal base, the effect of solvent and
temperature were evaluated and results are shown in Table 2.2. A nonpolar solvent, toluene, results in
nearly identical enantioselectivity, when compared to the standard solvent methylene chloride, except
with a dramatic decrease in yield to 17%. In contrast, acetonitrile reduced the enantioselectivity to 26 %
ee, but formed the product in similar efficiency (47%) to methylene chloride. Interestingly, production of
2-15 is nearly eliminated when using tetrahydrofuran (THF) with respectable recovery of starting material.
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After confirming dichloromethane as a suitable solvent for the DKAT, temperature effects on
enantioselectivity were explored. Phosphorylation of 2-14 at -40 °C, 0 °C and 25 °C respectively resulted
in enantioselectivities of 44%, 49%, and 45% ee respectively. Therefore, the optimal temperature was
determined to be 0 °C, but a smaller than expected influence on enantioselectivity was observed. In
addition, the product was obtained in the highest yield at 0 °C (58%), while increasing or decreasing the
temperature results in a reduction in yield.

Table 2.2 Effect of solvent and temperature on the phosphorylation reaction
Entrya
Solvent
T (°C)
Yield (%)b
ee (%)c

a

1

THF

0

4

55

2

Toluene

0

17

51

3

CH3CN

0

47

26

4

CH2Cl2

0

58

49

5

CH2Cl2

25

53d

45

6

CH2Cl2

-40

7e

44

Conditions: 2-13 (1 equiv.), CCl4 (4 equiv.), PhOH (1 equiv.), i-Pr2NEt (2 equiv.), 2-16 (20 mol %), solvent (0.1

M solution), 7 h; b Yields were determined by HPLC analysis; cee values were determined by HPLC analysis; d2
hours; e16 hours.
To assess the H-phosphinate substrate scope, the alcohol and the aryl group were varied a
coupled with phenol under the optimized reaction conditions (Table 2.3). Of note, the experiments in
Table 2.3 were performed with an altered stoichiometry (0.5 equiv. of alcohol) to improve the
enantioselectivity of the transformation at the expense of chemical yield. The products (2-25 – 2-28) of
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ethyl substituted H-phosphinates are obtained in comparable enantioselectivities, but with typically
higher yield due to the decreased steric environment around the phosphorus center (Table 2.3 Entry 36). As an aside, the HPLC elution order of methyl-substituted phosphonate (2-24) was reversed compared
to other synthetic phosphonate analogues due to indeterminate interactions with the stationary phase
(Figure C3 in appendix C). Modulation of the aromatic group on the H-Phosphinate was also investigated.
When dramatically altering the steric environment around the phosphorus by replacing the phenyl group
with an o-tolyl (Entries 3 and 4), the yield is unsurprisingly decreased from 95% to 67%. Similarly, the
increased steric hindrance did not improve the enantioselectivity. Additionally, electronic effects were
studied by substituting the phenyl group with a 4-methoxy- and a 4-fluoro-phenyl group, respectively. A
decline in enantioselectivity to 22% ee was obtained with both the electron-withdrawing and donating
substituents as shown in Table 2.3 Entries 5 and 6. The substrate scope for the H-phosphinate coupling
was found to be very sensitive to the steric and electronic environment around the phosphorus center
with improved yields and enantioselectivities observed than the model substrate (2-13), but with highly
varied results even under the optimized conditions.
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Table 2.3 Effect of electrophile on phosphorylation reaction
Entrya

R’

Product

Yieldb(%)

eec(%)

1

i-Pr

Ph

47
40d

55
-54d

2

Me

Ph

33

61

Et

Ph

95

62

Et

2-MePh

67

48

Et

4-OMePh

88

22

Et

4-F-Ph

93

22

3

4

5

6

a

R

Conditions: 2-11 (1 equiv.), CCl4 (4 equiv.), PhOH (0.5 equiv.), i-Pr2NEt (2 equiv.), 2-16. 20 mol %, CH2Cl2 (0.1 M

solution), 7 h; bIsolated yield; cee values were determined by HPLC analysis; d(R)-(2-16) was used.
In the process of exploring the substrate scope in Table 2.3, known compounds 2-24 and 2-25
were prepared to correlate the observed enantioselectivity to an absolute configuration. High
Performance Liquid Chromatography (HPLC) on a chiral stationary phase was used to measure all
enantioselectivities reported. As seen in Figure 2.2, using a normal phase eluent of hexane and ethanol
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with 0.1% trifluoroacetic acid (TFA) baseline resolves a racemic sample of 2-25 (red trace) formed when
no chiral catalyst is used. The enantioenriched product from Table 2.3 Entry 3 shows the correlating
imbalance in peak areas (62% ee) when using (-)- or (S)-benzotetramisole (Figure 2.2, black trace).
Correspondingly, the enantioenriched product from Table 2.3 Entry 3 has a measured [α]20
D of +21.7° (c
0.429, CHCl3). Using the published data and sign for (R)-2-25 ([α]20
D +34.4° (c 2.16, CHCl3), we observe that
(S)-BTM produces the (R) enantiomer of 2-25 as the major product.102 In addition, (R)-2-24 was produced
using (S)-BTM and agrees with reported values.102 Finally, when the enantiomer of the catalyst ( (R)-2-16
) was used to synthesize 2-15, a near-equal yield but opposite enantioselectivity (-54% ee) was observed,
as expected.

Figure 2.2 HPLC chromatogram of racemic (red) and chiral phosphonate analogues (black) of (2-25) using
(S)-2-16. Conditions. Phenomenex Lux Amylose-2 chiral column (250 X 4.6 mm), eluent = hexane: ethanol
(15 : 95 to 20 : 80 ) with 0.1% TFA, detection = 254 nm, flow rate = 0.5 ml/min, temperature = 25 °C.
Using catalyst (S)-2-16, a number of alcohols were tested as nucleophiles in the phosphorylation
reaction to produce the corresponding phosphonates in Table 2.4. Our standard phosphorylation reaction
utilized an aromatic alcohol (2-14) as a nucleophile so it was encouraging that BTM was an effective
catalyst for alcohols like allyl, benzyl, methyl, or phenethyl alcohol. Under the optimized conditions, allyl
alcohol, which differs greatly in structure from phenol, reacted with isopropyl-H-phosphinate in similar
efficiency (49% yield and 43% ee). Small decreases in enantioselectivity (28% and 35% ee) were observed
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when using phenethyl alcohol or benzyl alcohol as nucleophiles, but comparable yields were obtained.
Under the optimized reaction conditions, S-BTM (2-16) provided the same stereochemical outcome of the
(R)-phosphonate analogues in Table 2.4. However, due to Cahn-Ingold Prelog rules the priority of the
substituents on phosphorus changed and resulted in the formation of (S)-2-31 – (S)-2-34. Finally, even
when using sterically unencumbered, methanol, the product (2-34) yield and enantioselectivity were not
decreased (56 % yield and 51% ee). Similar to compound 2-24, the HPLC elution order of the methyl
phosphonate analogue (2-34) was reversed from the normal pattern (Appendix Figure C13). Moreover,
(S)-2-34 had a positive specific optical rotation of +0.1856° (c 0.5388, CHCl3), which is consistent with
analogous phosphonates.103
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Table 2.4 Effect of the nucleophile on the phosphorylation reaction
Entrya

Product

Yieldb (%)

ee (%)c

1

Phenol

47

55

2

allyl alcohol

49

43

3

2-phenethyl
alcohol

68

28

51

35

56

51

4

5

a

ROH

Benzyl alcohol

Methanol

Conditions: 2-13 (1 equiv.), CCl4 (4 equiv.), alcohols (0.5 equiv.), i-Pr2NEt (2 equiv.), 2-16 (20 mol %), CH2Cl2 (0.1 M

solution), 7h; bIsolated yield; cee values were determined by HPLC analysis.
The (-)-bezotetramisole (2-16) has offered the highest yield and enantioselectivity among the
nucleophilic catalysts tested. From a structural point of view, the chiral center is in close proximity to the
nucleophilic nitrogen but is not too hindered to suppress nucleophilic catalysis (Figure 2.3). The adjacent
sulfur and nitrogen atoms are a necessary component of the BTM catalyst by contributing greatly to the
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nucleophilicity. In contrast, the aromatic ring is sparsely substituted and provides the ability to modulate
the reactivity of the benzotetramisole structure for future catalyst development.

Figure 2.3 Structural analysis of asymmetric catalyst 2-16

Based on the Atherton-Todd reaction, a mechanism is proposed that explains the formation of
enantioenriched phosphonates (2-25) using the chiral nucleophilic catalyst 2-16.104 First, chlorination of
the H-phosphine moiety (2-35) using tetrachloromethane, as the stoichiometric oxidant result in the
formation of racemic phosphonochloridate 2-36 (Scheme 2.3). While monitoring the reaction using 31P
NMR, a species (29.3 ppm) consistent with a phosphonochloridate (2-36) was observed with concomitant
consumption of the H-phosphinate.105 Next, catalyst (S)-(2-16) attacks the phosphonochloridate and
results in diastereomers 2-37 and 2-38 after substitution of the chlorine. Unfortunately, 31P NMR did not
allow unambiguous identification of an intermediate where the BTM catalyst was bonded to the
phosphoryl center. Substitution reactions at the phosphorus atom typically involve either 1) a dissociative
SN1-type mechanism through the formation of stable metaphosphate (PO3-) or 2) an associative, two-step
addition-elimination mechanism through the formation of a phosphorane intermediate.36 In this case, the
elementary steps of the substitution process are inconsequential to the product outcome.
Nucleophilic addition by phenol forms pentavalent intermediates 2-39 and 2-40. Additional
pentavalent intermediates are likely formed in the reaction but not shown in Scheme 2.3. Elimination of
the BTM catalyst from the apical position of intermediate 2-39 provides the observed product 2-25 in the
observed (R) configuration.36 Elimination from pentavalent 2-39 is preferrable to elimination from 2-40
37

because steric interactions between the phenyl groups on the phosphonate and the catalyst (S)-(2-16) are
avoided. Alternatively, the stereoselectivity could be a result of π-π or π-cation interactions between the
catalyst and phosphorus substrate analogous to previously published acylation studies with 2-16.95 It is
known in the literature that trigonal bipyramidal phosphorus centers, such as 2-39 and 2-40, readily
undergo pseudorotation and provide an equilibration mechanism consistent with the dynamic kinetic
transformation observed.36 Alternatively, as mentioned above this could not be spectroscopically
observed. Thus, enantiomeric enrichment is a result of the faster elimination (k1 > k2) of 2-39 and
constitutes the stereodetermining step.

Scheme 2.3 Proposed asymmetric phosphorylation mechanism based on the dynamic kinetic
asymmetric transformation of H-phosphinate 2-35 to phosphonate into (R)-2-25 and (S)-2-25 using
chiral nucleophilic catalyst 2-16.

Collectively, the reaction stereoselectivity was dependent on the solvent, catalyst structure &
loading, and the nature of the base. The proposed mechanism explains the enantioselectivity dependence
on the reaction conditions perturbing the relative rates of elimination (k1, k2). The similarity of these rates
of elimination result in the modest stereoselectivity observed in this study. In contrast, the
enantioselectivity was largely unaffected by reaction temperature indicating kinetic control was observed
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as opposed to thermodynamic control. Finally, the proposed reaction mechanism in Scheme 2.3 shows
the selective formation of the (R)-phosphonate using (S)-(-)-benzotetramisole catalyst (2-16) consistent
optical rotations and absolute configurations.102 Modifying the BTM catalyst, by increasing the steric
hindrance of the phenyl group or electronically perturbing the fused benzo- system, may provide an
opportunity to improve the stereoinduction.

2.3

Conclusion
A dynamic kinetic transformation that produces stereogenic-phosphorus centers using an

asymmetric nucleophilic catalyst was developed. Alcohols, both aliphatic and aromatic, were coupled to
racemic H-phosphinates under halogenation conditions. After optimization of the solvent, base
temperature and catalyst loading, benzotetramisole was observed to provide asymmetric phosphonates
in acceptable yield (33% - 95%) with moderate enantioselectivity (up to 62% ee). The reaction conditions
were tolerant to a variety of alcohol and H-phosphinate substrates. Furthermore, a mechanism of
selective phosphorylation was proposed that accounts for the stereoselectivity. Future development of
the benzotetramisole catalyst could improve enantioselectivity and enable the synthesis of prodrugs for
pharmaceutical or biological application.

2.4

2.4.1

Materials and Methods

General information

All reactions were carried out under a nitrogen atmosphere in oven-dried glassware. The products were
purified by flash column chromatography using silica gel 60 (230-400 mesh Silicycle, Quebec, Canada).
Solvent, reagents, and chemicals were received from a commercial vendor and further dried under
activated 4 Å molecular sieves. Methylene chloride and THF were dried using the PURE SOLV MICRO
purification system. Thin-layer chromatography (TLC) analysis was performed on Merck 0.25 mm silica gel
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60 F254 plates. 1H-NMR was recorded using an Oxford Varian Unity Instrument at 400 MHz and referenced
using the residual solvent peak of CDCl3 at 7.26 ppm. 13P NMR spectra were acquired at 162 MHz and
externally referenced to 85% H3PO4 at (0 ppm). The 13C NMR were acquired at 101 MHz and referenced
to 77.1 ppm for CDCl3 solvent. The NMR data were processed with MestReNova11 NMR software. HPLC
was performed using the Gilson GX-271 instrument at 254 nm with Trilution LC software V3. Analytical
HPLC was carried out using a 5 m 250 x 4.6 mm Phenomenex Lux chiral column (Amylose-2 or Cellulose2). In analytical HPLC, the normal phase separation method used was: eluent hexane: ethanol (15 : 95 to
20 : 80 ) with 0.1% TFA, detection ( 254 nm), flow rate ( 0.5 ml/min), temperature ( 25 °C) and run time
(20 minutes). Mass spectra were measured by University of Illinois Mass Spectrometry Laboratory using
electrospray ionization technique (ESI). The optical rotations were measured for purified sample using
digital polarimeter JASCO (model DIP-370). Specific rotation ([α]20
D ) was reported for samples in solution
at 20 °C in which the symbol D represents the sodium D line with wavelength of light is 589 nanometers
and concentration in units of g/100ml.

2.4.2

Isopropyl phenyl-H- phosphinate (2-13)

A mixture of phosphinic acid (1.000 g, 7.04 mmol, 1 equiv.) and isopropanol (10 ml, 0.131 mol, 18.6 equiv.)
was stirred in a well-sealed, 20 ml vial for 15 hours at 138 °C. Then, the solvent was evaporated under
vacuum. The crude product was purified using silica gel column chromatography with 5% MeOH: 95%
CH2Cl2 as an eluent to provide a colorless oil in 70% yield (0.90 g). The NMR data matched previously
published results.106 1H NMR (400 MHz, CDCl3) δ 7.81 – 7.70 (m, 2H), 7.59 (d, J = 558.7 Hz, 1H, PH), 7.607.52 (m, 1H), 7.52 – 7.44 (m, 2H), 4.73 – 4.67 (m, 1H, OCH), 1.41 (d, J = 6.1 Hz, 3H, CH3), 1.33 (d, J = 6.1 Hz,
3H, CH3). 13C NMR (101 MHz, CDCl3) δ 133.1 (d, J = 2.9 Hz), 131.0 (d, J = 11.9 Hz), 130.6 (d, J = 133.0 Hz),
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128.8 (d, J = 13.9 Hz), 71.5 (d, J = 5.5 Hz), 24.4 (d, J = 4.5 Hz), 24.0 (d, J = 4.2 Hz).31P NMR (162 MHz, CDCl3)
δ 22.5 (d, J = 21.5 Hz).

2.4.3

Ethyl Phenyl-H-phosphinate (2-35)

A mixture of phosphinic acid (1.00 g, 7.04 mmol, 1 equiv.) in ethanol (10 ml, 0.171 mol, 24.4 equiv.) was
stirred in a well-sealed, 20 ml vial for 15 hours at 133 °C. Then, the solvent was evaporated under vacuum.
The product was purified by flash silica gel column chromatography using 5% MeOH: 95% CH2Cl2 as an
eluent to produce a colorless oil in 55% yield (0.65 g). The NMR data matched previously published
results.91 1H NMR (400 MHz, CDCl3) δ 7.74 (m, 2H), 7.59–7.51 (m, 1H), 7.54 (d, J = 562.5 Hz, 1H, PH), 7.50
– 7.42 (m, 2H), 4.17 – 4.05 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H).13C NMR (101 MHz, CDCl3) δ 133.2 (d, J = 2.8
Hz), 131.0 (d, J = 11.9 Hz), 129.9 (d, J = 132.3 Hz), 128.9 (d, J = 13.9 Hz), 62.3 (d, J = 6.5 Hz), 16.5 (d, J = 6.5
Hz). 31P NMR (162 MHz, CDCl3) δ 24.96 (d, J = 19.3 Hz).

2.4.4

Methyl Phenyl-H-phosphinate (2-40)

A mixture of phosphinic acid (1 g, 7.04 mmol, 1 equiv.) in methanol (15 ml, 0.370 mol, 52.9 equiv.) was
stirred in a well-sealed, 20 ml vial for 15 hours at 125 °C. Then, the solvent was evaporated under vacuum.
The crude product was purified by flash silica gel column chromatography using 5% MeOH: 95% CH2Cl2 as
an eluent to produce a colorless oil in 62% yield (0.68 g). The NMR data matched previously published
results.107 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.73 (m, 2H), 7.65–7.56 (m, 1H), 7.56 (d, J = 565.8 Hz, 1H,
PH), 7.55 – 7.47 (m, 2H), 3.79 (d, J = 12.0 Hz, 3H).13C NMR (101 MHz, CDCl3) δ 133.4 (d, J = 2.8 Hz), 131.2
(d, J = 11.9 Hz), 130.3 (d, J = 47.2 Hz), 129.0 (d, J = 13.8 Hz), 52.3 (d, J = 6.6 Hz). 31P NMR (162 MHz, CDCl3)
δ 27.46 (d, J = 21.6 Hz).
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2.4.5

Ethyl (2-methylphenyl)-H-phosphinate (2-41)

A solution of P(OEt)3 (0.970 g, 5.84 mmol, 1 equiv.) in diethylether (0.71 ml) was added dropwise under
N2 to a solution of o-tolyl magnesium bromide (5.14 ml, 2 M, 10.28 mmol, 1.75 equiv.) in diethyl ether.
After stirring the mixture at 34 °C for 5 hours, a solution of 1 M HCl is added at room temperature until
the pH of the solution was 2. After stirring the mixture for another hour, the mixture was extracted with
ethyl acetate (2 ml x 4). The combined organic layers were dried over MgSO4. The solvent was removed
under reduced pressure and purified by flash chromatography on silica gel using (5% MeOH: 95% CH2Cl2)
to give an oily product in 63% yield (0.675 g). 1H NMR (400 MHz, CDCl3) δ 7.77 (m, 1H), 7.60 (d, J = 555.1
Hz, 1H, PH), 7.48 – 7.40 (m, 1H), 7.29 (m, 1H), 7.26–7.19 (m, 1H), 4.13 (m, J = 8.8, 7.1 Hz, 2H), 2.53 (s, 3H),
1.34 (t, J = 7.1 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 141.2 (d, J = 10.8 Hz), 133.1 (d, J = 3.2 Hz), 132.1 (d, J
= 7.2 Hz), 131.3 (d, J = 5.0 Hz), 128.2 (d, J = 131.1 Hz), 126.0 (d, J = 14.1 Hz), 62.2 (d, J = 6.0 Hz), 20.1 (d, J
= 6.9 Hz), 16.5 (d, J = 3.1 Hz).31P NMR (162 MHz, CDCl3) δ 25.93 (d, J = 14.8 Hz).

2.4.6

Ethyl (4-methoxyphenyl)-H-phosphinate (2-42)

A solution of P(OEt)3 (0.1 g, 0.602 mmol, 1 equiv.) in THF (1.2 ml) was added dropwise under N2 to a
solution of 4-methoxyphenylmegnesium-bromide (1.8 ml, 0.5 M, 0.900 mmol, 1.5 equiv.) in THF. After
stirring the mixture at 66 °C for 5 hours, a solution of 1 M HCl is added at room temperature until the pH
of the solution is 2. After stirring the mixture for another hour, the mixture was extracted with ethyl
acetate (2 ml x 4). The combined organic layers were dried over MgSO4. The solvent was removed under
reduced pressure and purified by flash chromatography on silica gel using (5% MeOH: 95% CH2Cl2) to give
an oily product in 87% yield (105 mg). The NMR data matched previously published results.91 1H NMR (400
MHz, CDCl3) δ 7.76 – 7.64 (m, 2H), 7.54 (d, J = 561.7 Hz, 1H, HP), 7.00 (m, 2H), 4.16 – 4.08 (m, 2H), 3.85 (s,
3H),1.36 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 163.5 (d, J = 3.2 Hz), 133.2 (d, J = 13.2 Hz), 121.3
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(d, J = 138.8 Hz), 114.5 (d, J = 14.9 Hz), 61.9 (d, J = 6.4 Hz), 55.6 – 55.5 (m), 16.6 (d, J = 6.6 Hz) 31P NMR
(162 MHz, CDCl3) δ 23.68 (d, J = 17.1 Hz).

2.4.7

Ethyl (4-fluorophenyl)-H-phosphinate (2-43)

A solution of P(OEt)3 (0.5 g, 3.01 mmol, 1 equiv.) in THF (3.67 ml) was added dropwise under N2 to solution
of 4-fluoro magnesium bromide (4.5 ml, 0.8 M, 3.60 mmol, 1.2 equiv.) in THF. After stirring the mixture at
66 °C for 12 hours, a solution of 1 M HCl is added at room temperature until the pH of the solution is 2.
After stirring the mixture for another hour, the mixture was extracted with ethyl acetate (2 ml x 4). The
combined organic layers were dried over MgSO4. The solvent was removed under reduced pressure and
purified by flash chromatography on silica gel using (5% MeOH: 95% CH2Cl2) to give an oily product in 27%
yield (153 mg). The NMR data matched previously published results.91 1H NMR (400 MHz, CDCl3) δ 7.81 –
7.73 (m, 2H,), 7.55 (d, J = 567.1 Hz, 1H, PH) 7.18 (m, 2H), 4.27 – 4.06 (m, 2H, OCH2),1.36 (t, J = 7.1 Hz, 3H,
CH3). 13C NMR (101 MHz, CDCl3) δ 167.2 (d, JCP= 3.2 Hz), 164.7 (d, JCF= 3.4 Hz), 133.8 (dd, JCP= 22.2 Hz JCF
= 4.1 Hz), 127.6 (dd, JCP = 7.3 Hz, JCF= 7.9 Hz), 116.4 (dd, JCP= 36.7 Hz, JCF = 6.5 Hz), 62.4 (d, JCP = 6.2 Hz),
16.5 (d, JCP= 6.6 Hz)31P NMR (162 MHz, CDCl3) δ 23.48 (d, J = 18.0 Hz).

2.4.8

General procedure for Isopropyl (Alkyl)- phenyl-phosphonate

To a 7 mL reaction vial under an atmosphere of N2 was added isopropyl phenyl-H-phosphinate (2-13) (0.1
g, 0.543 mmol, 1 equiv.) and carbon tetrachloride (0.210 mL, 2.17 mmol, 4 equiv.). Next, anhydrous CH2Cl2
(0.3 M solution) was added and the solution cooled to 0 °C. A solution of N,N-diisopropylethylamine (0.14
g, 1.08 mmol, 2 equiv.), benzotetramisole (2-16) (0.027g 0.11 mmol, 0.2 equiv.), and an alcohol (0.27
mmol, 0.5 equiv.) that was previously dried over 4 Å molecular sieves, in anhydrous CH2Cl2 (0.3 ml) was
prepared. The alcohol solution was added dropwise to the original phosphinate solution and stirred for 9
hours at 0 °C. The mixture quenched with 1M HCl (1 ml) and extracted three times with ethyl acetate then
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dried using NaSO4. The product was purified by silica gel chromatography with ethyl acetate: hexane
(30:70) as an eluent. The following products were synthesized.
2.4.8.1

(R)-Isopropyl (Phenyl)-phenyl-phosphonate (2-15)
Yield 35 mg (47%). The NMR data were matched for previously published results.79 1H NMR (400

MHz, CDCl3) δ 7.89 – 7.82 (m, 2H), 7.56 – 7.50 (m, 1H), 7.47 – 7.41 (m, 2H), 7.25 (t, J = 7.9 Hz, 1H), 7.16 –
7.12 (m, 2H), 7.12 – 7.06 (m, 3H), 4.91 – 4.81 (m, 1H), 1.35 (d, J = 6.2 Hz, 3H), 1.30 (d, J = 6.2 Hz, 3H). 13C
NMR (101 MHz, CDCl3) δ 150.8 (d, J = 7.3 Hz), 132.7 (d, J = 7.9 Hz), 132.1 (d, J = 16.1 Hz), 129.7 (d, J = 7.7
Hz), 128.6 (d, J = 25.9 Hz), 128.6 (dd, J = 108.8, 82.8 Hz), 120.8 (d, J = 2.6 Hz), 72.3 (d, J = 5.9 Hz), 24.1 (d, J
= 2.3 Hz), 24.0 (d, J = 5.6 Hz).31P NMR (162 MHz, CDCl3) δ 14.92. [α]20
D +15.1° (c 0.26, CHCl3, 55 % ee). The
absolute configuration of compound 2-15 is designated the (R)-configuration based on the optical rotation
of previously published analogue 2-25.
2.4.8.2

(S)-Isopropyl (Allyl)-phenyl-phosphonate (2-31)

Yield 31.8 mg (49%). 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.74 (m, 2H), 7.56 – 7.49 (m, 1H), 7.47 – 7.39 (m,
2H), 5.90 (m 2H), 5.30 (dq, J = 17.1, 1.6 Hz, 2H), 5.18 (dq, J = 10.4, 1.4 Hz, 1H), 4.73 (m, 1H), 4.58 – 4.41
(m, 1H), 1.30 (dd, J = 48.2, 6.2 Hz, 6H).13C NMR (101 MHz, CDCl3) δ 133.1 (d, J = 6.5 Hz), 132.5 (d, J = 2.2
Hz), 131.9 (d, J = 10.0 Hz), 130.0 (s), 128.6 (d, J = 15.2 Hz), 71.3 (d, J = 6.6 Hz), 66.4 (d, J = 4.7 Hz), 24.2 (d,
J = 3.6 Hz), 24.0 (d, J = 4.9 Hz). 31P NMR (162 MHz, CDCl3) δ 18.53. HRMS (ES): m/z [M+H]+: calcd for
C12H18O3P 241.0994; found: 241.0983. [α]20
D -1.30° (c 0.23, CHCl3). The absolute configuration of
compound 2-31 is designated to be the (S)-configuration based on the analogous reactivity of 2-25.
2.4.8.3

(S)-Phenethyl (Isopropyl)-phenyl-phosphonate (2-32)

Yield 55.9 mg (68%). 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.68 (m, 2H), 7.54 – 7.48 (m, 1H), 7.44 – 7.36 (m,
2H), 7.30 – 7.14 (m, 5H), 4.73 – 4.60 (m, 1H), 4.30 – 4.08 (m, 2H), 2.97 (t, J = 7.1 Hz, 2H), 1.27 (dd, J = 41.1,
6.2 Hz, 6H).13C NMR (101 MHz, CDCl3) δ 137.5 (s), 132.4 (d, J = 6.9 Hz), 131.9 (d, J = 8.0 Hz), 129.2 (d, J =
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2.8 Hz), 129.0 (d, J = 188.6 Hz), 128.6 (d, J = 2.2 Hz), 128.5 (d, J = 9.6 Hz), 126.8 (d, J = 2.8 Hz), 71.2 (d, J =
14.7 Hz), 66.4 (d, J = 5.6 Hz), 37.1 (d, J = 6.7 Hz), 24.2 (d, J = 9.0 Hz), 24.0 (d, J = 9.9 Hz).31P NMR (162 MHz,
CDCl3) δ 18.15.HRMS (ES)+: m/z [M+H]+ calcd for C17H22O3P: 305.1307; found: 305.1302. [α]20
D -2.94° (c
0.68, CHCl3). The absolute configuration of compound 2-32 is designated to be the (S)-configuration based
on the analogous reactivity of 2-25.
2.4.8.4

(S)-Benzyl (Isopropyl)-phenyl-phosphonate (2-33)

Yield 40 mg (51%). 1H NMR (400 MHz, CDCl3) δ 7.84 – 7.77 (m, 2H), 7.55 – 7.50 (m, 1H), 7.43 (m, 2H), 7.35
– 7.26 (m, 5H), 5.04 (m 2H), 4.73 (m, 1H), 1.29 (dd, J = 37.2, 6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 136.5
(d, J = 7.2 Hz), 132.5 (d, J = 3.0 Hz), 131.9 (d, J = 9.9 Hz), 129.0 (d, J = 189.1 Hz), 128.6 (s), 128.5 (s), 128.4
(s), 127.9 (s), 71.4 (d, J = 4.0 Hz), 67.4 (d, J = 5.1 Hz), 24.2 (d, J = 4.1 Hz), 24.0 (d, J = 4.9 Hz). 31P NMR (162
MHz, CDCl3) δ 19.25. HRMS (EI) m/z [M+H]+ calcd for C16H19O3P: 290.10719; found: 290.10667. [α]20
D 6.309 (c 0.44, CHCl3). The absolute configuration of compound 2-33 is designated to be the (S)configuration based on the analogous reactivity of 2-25.
2.4.8.5

(S)-Isopropyl (Methyl)-phenyl-phosphonate (2-34)

Yield 32.4 mg (56%). The NMR data were matched for previously publish results.79 1H NMR (400 MHz,
CDCl3) δ 7.80 – 7.73 (m, 2H), 7.54 – 7.48 (m, 1H), 7.45 – 7.38 (m, 2H), 4.70 (m J = 2H), 3.68 (d, J = 11.2 Hz,
3H), 1.35 (d, J = 6.2 Hz, 3H), 1.22 (d, J = 6.2 Hz, 3H).13C NMR (101 MHz, CDCl3) δ 132.5 (d, J = 2.9 Hz), 131.9
(d, J = 9.8 Hz), 128.6 (d, J = 15.0 Hz), 128.6 (d, J = 188.7 Hz), 71.3 (d, J = 5.4 Hz), 52.5 (d, J = 2.8 Hz), 24.2 (d,
J = 3.9 Hz), 24.0 (d, J = 4.9 Hz). 31P NMR (162 MHz, CDCl3) δ 19.12. [α]20
D +0.1856° (c 0.5388, CHCl3). The
absolute configuration of compound 2-34 is designated to be the (S)-configuration based on the analogous
structure (S)-Ethyl (Methyl)-phenyl-phosphonate.103
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2.4.9

(R)-Methyl (Phenyl)-phenyl-phosphonate (2-24)
To a 7 mL reaction vial under an atmosphere of N2 was added methyl phenyl-H- phosphinate (2-

40) (0.1 g, 0.641 mmol, 1.0 equiv.) and carbon tetrachloride (0.234 mL, 2.422 mmol, 3.8 equiv.). Next,
anhydrous CH2Cl2 (0.3 M solution) was added and the solution cooled to 0 °C. A solution of N,Ndiisopropylethylamine (0.16 g, 1.211 mmol, 2 equiv.), benzotetramisole (S)-2-16 (0.031 g, 0.121 mmol,
0.19 equiv.), and phenol (28.2 mg, 0.300 mmol, o.47 equiv.) that was previously dried over 4 Å molecular
sieves, was prepared in anhydrous CH2Cl2 (0.3 ml). The alcohol solution was added dropwise to the
phosphinate solution and stirred for 9 hours at 0 °C. The mixture was quenched with 1 M HCl (1 ml) and
extracted three times with ethyl acetate then dried with Na2SO4. The product was purified by silica gel
chromatography with ethyl acetate: hexane (50:50) as eluent. The NMR data matched previously
published results.79 Yield 24.6 mg, (33%). 1H NMR (400 MHz, CDCl3) δ 7.86 (m, 1H), 7.59 – 7.52 (m, 2H),
7.50 – 7.42 (m, 1H), 7.29 – 7.23 (m, 2H), 7.17 – 7.07 (m, 5H), 3.84 (d, J = 11.3 Hz, 1H).13C NMR (101 MHz,
CDCl3) δ 150.7 (d, J = 7.2 Hz), 133.1 (d, J = 3.0 Hz), 132.2 (d, J = 10.1 Hz), 129.8 (s), 128.8 (d, J = 15.5 Hz),
127.1 (d, J = 191.0 Hz), 125.1 (s), 120.7 (d, J = 4.5 Hz), 53.31 (d, J = 3.5 Hz). 13C NMR (101 MHz, CDCl3) δ
150.7 (d, J = 7.2 Hz), 133.1 (d, J = 3.0 Hz), 132.2 (d, J = 10.1 Hz), 129.8 (s), 128.8 (d, J= 15.5 Hz), 127.4 (d, J
= 115.1 Hz), 125.1 (s), 120.7 (d, J = 4.5 Hz), 53.3 (d, J = 3.5 Hz). 31P NMR (162 MHz, CDCl3) δ 17.39 (s). [α]20
D
+54.66° (c 0.2049, CHCl3). The absolute configuration of compound 2-24 was determined to be (R)configuration based on the previously published optical rotation of the 2-24 ([α]20
D +38.1° (c 1.45, CHCl3)
which was defined using chiral shift reagents.102

2.4.10 General procedure for synthesis Ethyl (Aryl)-phenyl-phosphonate
To a 7 mL reaction vial under an atmosphere of N2 was added ethyl aryl-H-phosphinate (2-35) (0.100 g,
0.588 mmol, 1 equiv.) and carbon tetrachloride (0.21 mL, 2.170 mmol, 3.7 equiv.). Next, anhydrous CH2Cl2
(0.3 ml solution) was added and the solution was cooled to 0 °C. A solution of N,N-diisopropylethylamine
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(0.140 g, 1.100 mmol, 1.9 equiv.), benzotetramisole (S)-2-16 (0.027 mg 0.110 mmol, 0.19 equiv.), and
phenol (24 mg, 0.25 mmol, 0.43 equiv.) that was previously dried over 4 Å molecular sieves, was prepared
in anhydrous CH2Cl2 (0.3 ml). The alcohol solution was added dropwise to the phosphinate solution and
stirred for 9 hours at 0 °C. The mixture was quenched with 1 M HCl (1 ml) and extracted three times with
ethyl acetate then dried with Na2SO4. The product was purified by silica gel chromatography with ethyl
acetate: hexane (30:70) as the eluent. The following products were synthesized.
2.4.10.1 (R)-Ethyl (Phenyl)- phenyl-phosphonate (2-25)
Yield 62.3 mg (95%). The NMR data were macheted with previously published results.79 1H NMR (400 MHz,
CDCl3) δ 7.91 – 7.81 (m, 2H), 7.59 – 7.51 (m, 1H), 7.50 – 7.40 (m, 2H), 7.28 – 7.23 (m, 2H), 7.16 – 7.07 (m,
3H), 4.29 – 4.18 (m, 2H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 150.7 (d, J = 7.0 Hz), 132.9
(s), 132.19 (d, J = 10.1 Hz), 128.7 (d, J = 15.5 Hz), 127.4 (d, J = 485.6 Hz), 126.9 (s), 124.1 (s), 120.7 (d, J =
4.5 Hz), 63.0 (d, J = 5.6 Hz), 16.5 (d, J = 7.3 Hz).31P NMR (162 MHz, CDCl3) δ 14.43 (d, J = 12.7 Hz). [α]20
D
+21.7° (c 0.429, CHCl3). The absolute configuration of compound 2-25 was determined to be the (R)configuration based on the previously published optical rotation of 2-25 ([α]20
D +34.4° (c 2.16, CHCl3) which
was defined using chiral shift reagents.102
2.4.10.2 (R)-Ethyl (2-methylphenyl)- phenyl-phosphonate (2-26)
Yield 46.3 mg (67%). 1H NMR (400 MHz, CDCl3) δ 7.91 – 7.82 (m, 2H), 7.29 – 7.23 (m, 2H), 7.17 – 7.07 (m,
5H), 4.29 – 4.18 (m, 2H), 1.33 (td, J = 7.1, 0.6 Hz, 3H).13C NMR (101 MHz, CDCl3) δ 167.0 (d, J = 3.9 Hz),
164.4 (d, J = 3.8 Hz), 150.6 (d, J = 7.4 Hz), 134.8 (dd, J = 11.6, 9.0 Hz), 129.8 (s), 125.1 (s), 120.7 (d, J = 4.6
Hz), 116.1 (dd, J = 21.5, 16.8 Hz), 63.2 (d, J = 6.1 Hz), 16.5 (d, J = 6.5 Hz). 31P NMR (162 MHz, CDCl3) δ 14.78.
HRMS (EI) m/z [M+H]+ calcd for C15H17O3P: 276.09154; found: 276.09189; [α]20
D +17.35 (c 0.5525, CHCl3).
The absolute configuration of compound 2-26 is designated to be the (R)-configuration based on the
analogous reactivity of 2-25.
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2.4.10.3 (R)-Ethyl (4-methoxyphenyl)-phenyl-phosphonate (2-27)
Yield 64.3 mg (88%). 1H NMR (400 MHz, CDCl3) δ 8.01 – 7.92 (m, 1H), 7.43 (m, 1H), 7.29 – 7.22 (m, 5H),
7.15 (m, 1H), 7.13 – 7.07 (m, 1H), 4.24 (m, 2H), 2.65 (d, J = 1.7 Hz, 3H), 1.33 (t, J = 7.1 Hz, 3H). 13C NMR
(101 MHz, CDCl3) δ 155.1 (d, J = 6.9 Hz), 146.4 (d, J = 10.4 Hz), 138.6 (d, J = 10.6 Hz), 137.3 (s), 135.8 (d, J
= 15.3 Hz), 134.1 (s), 130.0 (d, J = 15.4 Hz), 129.2 (s), 124.8 (d, J = 4.4 Hz), 67.7 (d, J = 6.0 Hz), 25.8 (d, J =
3.4 Hz), 20.7 (d, J = 6.4 Hz).31P NMR (162 MHz, CDCl3) δ 16.84. HRMS (EI) m/z [M+H]+ calcd for C15H17O4P:
292.08645; found: 292.08532. [α]20
D +9.68 (c 0.6713, CHCl3). The absolute configuration of compound 227 is designated to be the (R)-configuration based on the analogous reactivity of 2-25.
2.4.10.4 (R)-Ethyl (4-fluorophenyl phenyl)- phenyl-phosphonate (2-28)
Yield 65.3 mg (93%). 1H NMR (400 MHz, CDCl3) δ 7.78 (m, 2H), 7.27 – 7.21 (m, 2H), 7.15 – 7.04 (m, 3H),
6.97 – 6.91 (m, 2H), 4.26 – 4.15 (m, 2H), 3.81 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ
163.3 (d, J = 3.4 Hz), 150.9 (d, J = 7.0 Hz), 134.2 (d, J = 11.6 Hz), 129.8 (s), 124.9 (s), 120.8 (d, J = 4.4 Hz),
119.0 (d, J = 198.1 Hz), 114.3 (d, J = 16.6 Hz), 62.8 (d, J = 5.5 Hz), 55.5 (d, J = 2.3 Hz), 16.5 (d, J = 6.6 Hz). 31P
NMR (162 MHz, CDCl3) δ 16.88. HRMS (EI)+ m/z [M+H]+: calcd for C14H14O3PF: 280.06646; found:
280.06528. [α]20
D +3.79 (c 0.5537, CHCl3). The absolute configuration of compound 2-28 is designated to
be the (R)-configuration based on the analogous reactivity of 2-25.
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CHAPTER THREE

3

3.1

ENANTIOSELECTIVE PHOSPHORYLATION OF ALCOHOLS USING PHOSPHORAMIDITES P(III)

Introduction

Organophosphorus compounds with chirality on phosphorus atoms are ubiquitous in agrochemicals,108
pharmaceuticals,

109

as organocatalysts reagent,110 and as ligands in metal-base complexes.111 Among

organophosphates, the trivalent phosphoramidite moiety is the most popular method for synthesizing
oligonucleotides on a solid support.112
Large-scale synthesis of oligonucleotides for RNA therapeutic applications has increased interest in the
phosphoramidite method of oligonucleotide synthesis.13 Phosphoramidite protocol evolved from the
phosphotriester method developed by Letsinger and Ogilvie.113,114 The development of the method came
from the replacement of the trivalent phosphorochloridite building blocks with more stable
phosphoramidite substrates. After being activated with Brønsted acid, the protected nucleoside 3’phosphoramidites (3-1) are coupled with the 5’-hydroxy of the solid-supported oligonucleotide as see in
Scheme 3.1.115

Scheme 3.1 Coupling step in phosphoramidite approach of oligonucleotide synthesis.
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Phosphoramidites (3-8) are a variant of trivalent phosphorus acid (H3PO3) where one of the P-O bonds has
been replaced with an amine as seen in Figure 3.1.116 Based on the trivalent nature of phosphorus, three
types of phosphorus amides can appear phosphoramidite (3-8), phosphordiamide (3-9), and
phosphortriamide (3-10). Both the phosphorus and nitrogen atoms in phosphoramidite have unshared
electron lone pairs which causes the phosphoramidite nitrogen to be basic and the resultant species is
highly reactive. According to X-ray analysis studies of phosphoramidite compounds, the phosphorus atom
has a pseudotetrahedral geometry while the nitrogen atom is trigonal planar.117,118

Figure 3.1 Trivalent phosphorus structures
Current synthetic approaches for trivalent stereogenic phosphorus moieties are depicted in
Scheme 3.2. Enantiopure phosphine borane complex (3-11) has been widely used as precursors for
diastereoselective nucleophilic substitution reactions. Thus, P-C or P-O bonds were selectively formed to
reach up to 90 % ee. The boron moiety works as a protecting group for strongly Lewis basic phosphorus
center, which can be removed with a basic amine as seen in Scheme 3.2a.36,119,120 However, harsh
conditions are required to prepare the borane complex resulting in limited substrate scope. Alternatively,
stereogenic-P(III) centers can be synthesized through the transformation of a prochiral substrate to a
chiral substance by the addition of a group as seen in Scheme 3.2b.121 However, desymmetrization of
prochiral substrates is limited by substrate scope and low enantioselective enrichment.
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Scheme 3.2 Synthetic approaches to P(III)-stereogenic organophosphorus compounds: a) Synthesis by
phosphine borane complex. b) Desymmerization of prochiral P(III)-substrate. c) Using a chiral auxiliary or
promotor for P(III)-stereogenic synthesis. d) Catalytic asymmetric synthesis. e) Asymmetric
phosphorylation via chiral nucleophilic catalyst: this work.
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Another strategy, relays chiral information into the transition state using an enzyme, chiral
auxiliary, chiral reagent, or catalyst as in Scheme 3.2c, d, e. For example, alcohols or amines have been
widely utilized as chiral auxiliaries because they can be readily attached to trivalent phosphorus moieties
as in Scheme 3.2c.37 However, a stoichiometric amount of a chiral auxiliary is always required to achieve
the desired stereoselectivity. Also due to a direct connection to a chiral auxiliary to the P(III) motif,
additional chemical processes are required to remove the chiral auxiliary and isolate the desired
product.37 The use of natural products or enzymes have been used as external asymmetric inducers for
the synthesis of trivalent phosphorus centers. Scott Miller et al. modified synthetic peptides, as an enzyme
mimic, for alcohol phosphorylation as in Scheme 3.2d.122 However, since the peptide catalyst interacts
with the substrate using unique and unpredictable non-covalent interactions, this method fails to provide
a general catalyst for the synthesis of stereogenic-P(III) molecules.
To avoid all these limitations, an enantioselective phosphitylation P(III) of alcohols has been
investigated using a chiral nucleophilic catalyst and racemic trivalent phosphoramidite substrate as seen
in Scheme 3.2e. This approach has several advantages. For example, a racemic substrate could be used to
produce enantiomerically enriched phosphorus centers using substoichiometric amounts of a chiral
catalyst. Also, the scope of phosphoramidite substrates could be expanded to include nucleotide
chemistry.

3.2

Results and Discussion
Before developing an enantioselective phosphoramidite coupling, conversion of phosphoramidite

3-11 to racemic phosphate analog 3-15 was accomplished in a one-pot, two-step process. First,
phosphitylation of chlorophenol with 3-11 occurred using a stoichiometric amount of 4,5dicyanoimidazole promotor. Then, the phosphite product was oxidized by tertbutyl peroxide to provide
the corresponding P(V) phosphate (3-15) as shown in Scheme 3.3.
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Scheme 3.3 Alcohol phosphitylation utilizing phosphoramidites followed by oxidation.
Phosphoramidites always require a stoichiometric amount of acid during an alcohol phosphitylation
reaction progress because P-N bond breaking generates an equivalent of an alkylamine as a byproduct.123–
125

As the concentration of the amine increases, the concentration of the promoter decreases as seen in

Scheme 3.3. Accordingly, Bradly et al. have demonstrated that isocyanates scavenge amines to enable
catalyst turnover by converting the amine byproduct to urea which is no longer basic and it doesn’t
deactivate the catalyst.125 Conversions up to 97% with 5 mol % of H-tetrazole catalyst were observed.125
Therefore, scavenging the amine byproduct should alter the equilibrium allowing the promoter to
function catalytically and overcome the conversion and catalyst deactivation limitations previously
documented with asymmetric phosphoramidite couplings.
The phosphate analog product 3-15 was isolated with a 70% yield and characterized using 31P and
1

H NMR. In addition, high performance liquid chromatography (HPLC) on a chiral stationary phase

indicated the racemic material contains a 50:50 ratio of two enantiomers as seen in Figure 3.2.
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Area = 28350.575

Area = 24094.892

Figure 3.2 HPLC chromatogram of racemic 3-15. Conditions: Phenomenex amylose-2 chiral column
(250 X 4.6 mm), eluent acetonitrile : water ( 60 : 40 – 80 : 20 ), detection at 254 nm, flow rate 0.5
ml/min, temperature at 25 °C.

Under the optimized conditions for the racemic formation of 3-15, addition of phenylisocyanate
(1 equiv.), as amine scavenger, and a number of chiral nucleophilic catalysts were screened to investigate
the enantiomeric enrichment of the phosphorus center (Scheme 3.4). Planar-chiral catalyst 3-18, also
known as Fu’s catalyst, is a ferrocene analogue of 4-Diethylaminopyridine (DMAP) that is known to behave
as a chiral nucleophilic catalyst. When using catalyst 3-18 along with 10 mol% of TFA, the product 3-15
was obtained 23% ee and 23% yield. TFA was included to protonate the pyridine of 3-18 and subsequently
the phosphoramidite, to facilitate P-N bond cleavage and allow the alcohol to attack the phosphoramidite.
Despite 3-18 being a proficient catalyst for the asymmetric substitution of acyl groups, it performs very
poorly in the asymmetric substitution of phosphoryl groups.
Based on the success in the asymmetric synthesis of phosphonates (Chapter 2), heterocyclic
nucleophilic catalyst 3-19 (BTM 2-16) was tested in the synthesis of P(V) phosphates. Disappointingly,
product 3-15 was obtained in only 21% ee and 15% yield. Similarly, imidazole 3-20 provides 3-15 in 16%
ee and only 8% despite it being useful for the synthesis of ProTideTM phosphates.
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Conditions: 3-11 (1 equiv.), ClPhOH (1 equiv.), PhNCO (1 equiv.), Cat. (10 mol %), CH2Cl2 (0.1 M
solution), 8 h; then t-BuOOH (5 equiv.). a ee values and yield were determined by HPLC analysis.
Scheme 3.4 A catalyst screening for asymmetric alcohol phosphitylation.

Catalysts 3-18, 3-19, and 3-20 all required addition of an exogenous acid to activate the
phosphoramidite for substitution. However, traditional phosphoramidite coupling utilizes acid azoles,
such as 1H-tetrazole, that have dual roles. First, the azole works as an acid to protonate the amine nitrogen
as a leaving group. The other role is as a nucleophilic activator to displace the protonated
diisopropylamine and form an activated intermediate. The intermediate then undergoes nucleophilic
substitution with an alcohol to provide the phosphate product.124
Using chiral 1H-tetrazole analog 3-16 (10 mol %) the phosphate product (3-15) was obtained
in 50% yield and 27% ee. Notably, the yield and enantioselectivity are highest observed results for 3-15
(Scheme 3.4). However, when compared with the desired enantioselectivity (>90% ee), the chiral site is
likely flexible to induce asymmetric phosphitylation of the alcohol. Alternatively, a chiral 1Hbenzimidazole analog 3-17, which has not previously been reported as as nucleophilic catalyst, provides
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3-15 in low enantioselectivity (13 % ee) and dramatically diminished yield (6 %). Thus, the asymmetric site
of both chiral H-tetrazole 3-16 and 1H-benamidiazole 3-17 were not enough to favor one enantiomer over
the other. However, the literature contains very few examples of using a substoichiometric amount of a
chiral compound to induce enantioselectivity in phosphoramidite couplings making the results in Scheme
3.4 still noteworthy.
Prior to identifying 3-16, which serves a dual catalytic role, trifluoroacetic acid (TFA) was used in
combination with chiral nucleophilic bases to facilitate phosphoramidite coupling. In order to improve the
modest enantioselectivities observed with TFA, the effect of acid and concentration were tested with
catalyst 3-18 as seen in Table 3.1.
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Table 3.1 Effect of acid on the catalytic phosphitylation
Entry

H+

[H+]

Yield (%)a

%eeb

1

HBF4

10 mol%

10

23

2

TFA

10 mol %

30

23

3

TFA

5 mol %

12

18

Conditions: 3-11 (1 equiv.), ClPhOH (1 equiv.), PhNCO (1 equiv.), 3-18 (10 mol %), tetrafluoroboric acid
(HBF4), trifluoroacetic acid (TFA) , CH2Cl2 (0.1 M solution), 8 h, then t-BuOOH (5 equiv.). a Yields were
determined by HPLC analysis. bee values were determined by HPLC analysis.

In contrast to TFA, 10 mol % of tetrafluoroboric acid (HBF4), a strong acid, was tested and the
selectivity did not change (23% ee) but the yield dropped from 30% to 10% (Table 3.1 Entry 1 and 2).
Possibly the phosphorus atom of the phosphoramidite can be protonated by HBF4 resulting in a species
that is less reactive towards nucleophilic attack.123,126,127 Decreasing the acid concentration (TFA) to 5 mol
%, decreased both the selectivity and yield of the product (3-15) to 18% ee and 12% respectively (Table
3.1 Entry 3). This result demonstrates the importance of the acid catalyst participation in the reaction.
The impact of solvent and temperature on the selectivity and yield of phosphate 3-15 was tested
and the results shown in Table 3.2. Dichloromethane is a nonpolar, aprotic solvent that provided the
product in 23% yield and 23% ee. Using a more solvent, acetonitrile, results in an equivalent or increased
yield (22% and 58%), but a decrease in enantioselectivity (17% and 4% ee) as shown in Table 3.2 Entry 5.
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In contrast, utilization of a nonpolar solvent, toluene, provided 3-15 in 30% yield and 22% ee. Future
studies with nonpolar solvents may provide increases in enantioselectivity and yield in this type of
transformation in the future. Finally, when tetrahydrofuran was used as a solvent, the reaction outcome
was 17% yield and 15% ee.

Table 3.2 Effect of the solvent and the temperature on the phosphoramidite phosphitylation
Entry

Solvent

T (°C)

Yield (%)a

%eeb

1

Toluene

0

30

22

2

THF

0

17

15

3

CH2Cl2

0

23

23

4

CH3CN

0

22

17

5

CH3CN

25
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4

Conditions: 3-11 (1 equiv.), ClPhOH (1 equiv.), PhNCO (1 equiv.), 3-18 (10 mol %), trifluoroacetic acid
(TFA) (10 mol %) , CH2Cl2 (0.1 M solution), 8 h, then t-BuOOH (5 equiv.). a Yields were determined by
HPLC analysis. bee values were determined by HPLC analysis.

Based on the above experimental data, a reasonable mechanism of enantioselective
nucleophilic substitution at phosphorus (SN2P) can be proposed (Scheme 3.5). A catalytic amount of chiral
1H-tetrazole analog 3-16 can react with racemic phosphoramidite (3-11) and form a diastereomeric
mixture of tetrazole phosphoramidites (3-12 and 3-13).124 In more detail, the chiral 1H-tetrazole analog 358

16 plays a dual role as a an acid to protonate the amine nitrogen and then as a nucleophilic catalyst to
displace the protonated diisopropylamine.124 Racemization of 3-12 and 3-13 by the chiral tetrazole causes
a dynamic kinetic resolution of two diastereomer allowing for the asymmetric transformation to
phosphite moiety (Rp)-3-15 and (Sp)-3-15.128 The thermodynamic stability of 3-12 and 3-13 are different
and thus exist at different concentrations during the reaction. More importantly, the reactivity of these
two diastereomeric intermediates is different, represented by k1 and k 2 in Scheme 3.5. Thus, the effective
resolution process is dependent on these reaction rates (ideally k 1 << k 2 or k 1 >> k 2). One equivalent of
the phenyl isocyanate additive in the reaction helps to increase the catalyst turnover by scavenging the
byproduct amine and converting it to a non-basic urea product whereby allowing the heterocycle to enter
the catalytic cycle again.

Scheme 3.5 Proposed mechanism of alcohol phosphitylation with phosphoramidites using
substoichiometric amounts of chiral tetrazole analog 3-16 based on a dynamic kinetic resolution.
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3.3

Catalyst Development

Scheme 3.6 Reaction sequence to produce 1H-tetrazole [2,2]paracyclophane (3-24)
Based on the effectiveness of chiral tetrazoles in the asymmetric synthesis of phosphates, synthetic
studies to obtain a planar chiral cyclophane that contains a 1H-tetrazole moiety (3-24) was pursued. First,
an aldehyde was installed on paracyclophane to get [2,2] paracyclophancarboxaldehyde (3-21). Aldehyde
3-21 is a key compound in the sequence because the enantiomers can be separated using a procedure
by Quici.129 To separate these enantiomers, aldehyde 3-21 was reacted with (S)-methylbenzylamine to
produce diastereomeric imines 3-22 in quantitative yield. Next, the diastereomers are separated using
recrystallization in n-hexane (Scheme 3.6). Cyclophane (S,R)-3-22 hydrolyzes under the acidic
environment of silica gel resulting in formation of cyclophane (R)-(3-21) in 96% ee and 22% yield (Figure
3.3). Isolation of (R,R)-3-22 from the filtrate can be pursued to obtain cyclophane (S)-(3-21) but requires
additional recrystallization to obtain the product in high enantioselectivity.
Subsequently, treatment of R-(3-21) with phosphoryl chloride in presence of sodium azide at 70 °C
for 17 hours gave nitrile product 3-23 in 75% yield. After thorough optimization, enantiopure nitrile 3-23
was converted into tetrazole 3-24 using zinc bromide and sodium azide in 10 % yield. The low product
yield in tetrazole formation is likely due to the sterically hindered environment of cyclophanes due to the
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close proximity of the aromatic rings. During the tetrazole formation, the product 3-24 was found to have
racemized under the high reaction temperature (180 °C). Since no milder methods could be found to
convert the nitrile into the tetrazole without racemization, the tetrazole would need to be formed before
resolution in order to obtain 3-24 in enantioenriched form.

Figure 3.3 HPLC chromatogram of 3-21. Conditions: Phenomenex amylose-2 chiral column (250 X 4.6
mm), eluent hexane: ethanol and 0.1% TFA (65:35), detection 254 nm. Flow rate 0.5 ml min-1,
temperature 25 °C.
Alternatively, catalyst development could be pursued to overcome the limitations of chiral 1Htetrazole synthesis and enantiomer separation. For example, borylation of cyclophane and subsequent
Suzuki coupling with a bromo-tetrazole could provide a chiral tetrazole-containing [2,2] cyclophane (3-30)
as shown in scheme 3.7. This strategy would require a chiral auxiliary on tetrazole to facilitate
diastereomer separation. Therefore, a [3+2] cycloaddition reaction of the sodium azide with (R)methylbenzylamine was carried out to produce a chiral methyl tetrazole analog (3-28) in 75% yield. Then,
tetrazole 3-28 was brominated to produce chiral bromo-tetrazole 3-29 in 90% yield. To facilitate a Suzuki
coupling, borylation of cyclophane was carried out in two steps to produce unstable, cyclophane boronic
acid 3-26 in 25% yield. The compound 3-26 was found to be unstable on silica gel column.
Finally, the Suzuki coupling product 3-30 needs to be hydrogenated to break the C-N bond and
produce compound 3-24 as seen in scheme 3.7.
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Scheme 3.7 Alternative reaction sequence to produce 1H-tetrazole [2,2]paracyclophane (3-24) by Suzuki
coupling reaction.

3.4

Conclusion and future direction

Asymmetric phosphorylation using P(III) phosphoramidites was carried out with a variety of chiral
nitrogen-containing heterocycles as catalysts. The reaction was performed in presence of phenyl
isocyanate as an amine scavenger to increase the catalyst turnover. Various conditions were screened
including solvent, temperature, acid, and chiral nucleophilic catalyst. (S)-5-(1-Boc-Pyrolidin-2-yl)-1Htetrazole (3-16) in CH2Cl2 below room temperature was determined to be the best condition for
phosphorylation with 23% ee and 49% yield. Despite the modest selectivity and yield, this approach has a
number of advantages including utilizing a catalytic amount of a chiral amine. If a more capable catalyst
were found, a wide range of enantioselective stereogenic phosphate mimics could be obtained using
suitable oxidation conditions such as phosphorothioates by sulfurization, phosphoselenoates by
selenation, or boranophosphates by boronation.
The synthesis of novel, chiral tetrazoles was pursued to identify a more selective catalyst. A chiral
cyclophane was produced with a 1H-tetrazole moiety using a resolution by a chiral amine and subsequent
conversion into the nitrile. However, the tetrazole-containing [2,2]-paracyclophane racemized during the
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synthesis process making it inoperative as a chiral nucleophilic catalyst. An alternative synthetic route
would need to be pursued to obtain the proposed tetrazole-containing [2,2]-paracyclophane.

3.5

3.5.1

Materials and Methods

General information

All reactions were carried out under a nitrogen atmosphere in oven-dried glassware. The products were
purified by flash column chromatography using silica gel 60 (230-400 mesh Silicycle, Quebec, Canada).
The solvent, reagents, and chemicals were received from a commercial vendor and further dried under
activated 4 Å molecular sieves. Methylene chloride and THF were dried using a Pure Solv Micro
purification system. Thin-layer chromatography (TLC) analysis was performed on Merck 0.25 mm silica gel
60 F254 plates. 1H NMR was recorded using an Oxford Varian Unity Instrument at 400 MHz spectrometers.
1

H NMR data was referenced using the residual solvent peak of CDCl3 at 7.26 ppm. 13P NMR spectra were

acquired at 162 MHz and externally referenced to 85% H3PO4 at (0 ppm). The 13C NMR were acquired at
101 MHz and referenced to 77.1 ppm for the CDCl3 solvent. The NMR data was processed with
MestReNova11 NMR software. HPLC was performed using the Gilson GX-271 instrument with Trilution LC
software (V3) and a 5μm 250 x 4.6 mm Phenomenex Lux Amylose chiral column. For analytical HPLC, the
reverse phase separation method used was: eluent acetonitrile: water ( 60:40-80:20 ), detection ( 254
nm), flow rate ( 0.5 ml/min), temperature ( 25 °C), and run time (20 minutes).
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3.5.2

Benzyloxy bis (N,N-diisopropyl)phosphordiamide (3-9)

To a 7 mL reaction vial under an atmosphere of N2 was added triethylamine (0.18 ml, 1.3 mmol, 1 equiv.).
Next, anhydrous acetonitrile (0.3 mL) was added followed by benzyl alcohol (130 mg, 1.2 mmol, 1 equiv.)
that was previously dried over 4 Å molecular sieves. A solution of bis(diisopropylamino)chloro-phosphine
(300 mg, 1.12 mmol, 1 equiv.) in dry ether (2.5 ml) was prepared and cooled to 0 °C. The alcohol solution
was added dropwise to the phosphine solution and stirred for 2 hours at 0 °C. After the reaction mixture
was stirred for 2 hours at 0 °C, a white precipitate formed that was filtered off. The filtrate was
concentrated dissolved in dry acetonitrile (3 ml). n-Hexane (2 x 1 mL) was added and the hexane layer was
collected. The solvent was removed under reduced pressure to provide a colorless oil product 3-9 (341
mg, 90 % yield). The crude product was found to be unstable to purification by silica gel chromatography,
so the product was used without further purification. 1H NMR matched literature data.130 1H NMR (400
MHz, CDCl3) δ 7.35 – 7.13 (m, 5H), 4.60 (d, J = 7.3 Hz, 2H), 3.52 (4H, m), 1.13 (24H, m), 31P NMR (162 MHz,
CDCl3) δ 124.70.
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3.5.3

Benzyloxy Cyclohexanol N, N-diisopropylphosphoramidite (3-11)

To a 7 mL reaction vial under an atmosphere of N2 was added 4,5-dicyanoimidazole (11 mg, 0.094 mmol,
0.5 equiv.). Next, anhydrous acetonitrile (0.3 mL) was added followed by hexanol (9 mg, 0.094
mmol, 0.5 equiv.) that was previously dried over 4 Å molecular sieves. A solution Benzyloxybis(diisopropylamino)phosphine (3-9) (63 mg, 0.187 mmol, 1 equiv.) in anhydrous in CH3CN (0.2 mL) was
prepared and cooled to 0 °C. The alcohol solution was added dropwise to the phosphine solution and
stirred for 30 minutes. After removing the ice bath, the reaction mixture was left stirring for another 30
minutes. n-Hexane (2 x 1 mL) was added and the hexane layer was collected. The solvent was removed
under reduced pressure to provide the product 3-11 (47 mg, 75% yield). The crude product was found to
be unstable to purification by silica gel chromatography, so the product was used without further
purification. After removing the solvent under reduced pressure, the product was isolated (47 mg, 75%
yield). 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.17 (m, 5H), 4.83 – 4.57 (2H, m), 3.66 (2H, m), 1.99 – 0.99 (22H,
m), 31P NMR (162 MHz, CDCl3) δ 145.52.
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3.5.4

General procedure for asymmetric phosphitylation

To a 7 mL reaction vial under an atmosphere of N2 was added chiral nucleophilic catalyst (3-18) (4.89 mg,
0.0074 mmol, 10 mol%), and trifluoroacetic acid (TFA) (0.84 mg, 0.0074 mmol, 10 mol %). Next, anhydrous
CH2Cl2 (0.2 mL) was added followed by chlorophenol (9.5 mg, 0.074 mmol, 1 equiv.) that was previously
dried over 4 Å molecular sieves. A solution Benzyloxy Cyclohexanol N,N-diisopropylphosphoramidite (311) (25 mg, 0.074 mmol, 1 equiv.) in anhydrous in CH2Cl2 (0.35 mL) was prepared. The alcohol solution
was added dropwise to the phosphoramidite solution. After 3 hours, the reaction was monitored with TLC
and 31P NMR to confirm phosphite production. The reaction mixture was cooled to 0 °C followed by
addition of a solution of tert-butyl hydrogen peroxide (0.04 ml, of 5.5 M solution in decane, 0.37 mmol).
The reaction was warmed to room temperature and left to stir for 5 hours. Then, the reaction was
quenched with aqueous NaHCO3, extracted three times with ethyl acetate, and dried with Na2SO4. The
product was purified by silica gel chromatography with ethyl acetate: hexane (10:90) as eluent. 1H NMR
and 31P NMR showed products with (9 mg, 54% yield). 1H NMR (400 MHz, CDCl3) δ 7.52 – 6.96 (m, 7H),
5.29 – 5.09 (m, 2H), 4.55 (qt, J = 8.9, 3.8 Hz, 2H), 2.01 – 1.01 (m, 10H), 1.00 – 0.65 (m, 1H), 31P NMR (162
MHz, CDCl3) δ -6.47.
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3.5.5

Synthesis (S)-5-(1-Boc-Pyrolidin-2-yl)1H-tetrazole (3-16)

To solution of (S)-5-(1H-Pyrolidin-2-yl)1H-tetrazole (50 mg, 0.359 mmol, 1 equiv.), and triethylamine (44
mg, 0.431 mmol, 1.2 equiv.) in CH2Cl2 (0.6 ml), a solution of di-tert-butyl dicarbonate (Boc2O) (78 mg,
0.359 mmol, 1 equiv.) in CH2Cl2 (0.6 ml) was added at 0 °C. After raising the temperature to room
temperature, the mixture was stirred for 16 hours until the TLC showed the starting material had been
consumed. Then, the crude product was purified by silica gel chromatography using MeOH: CH2Cl2 (10:90).
The product Yield 59 mg (69% yield). The NMR data were matched for previously publish results.131 1H
NMR (400 MHz, CDCl3) δ 5.09 (dd, J = 8.3, 2.6 Hz, 1H), 3.49 (s, 1H), 2.76 (ddd, J = 10.8, 5.4, 2.2 Hz, 1H),
2.41 – 1.89 (m, 1H), 1.45 (s, 10H), 1.31 – 1.20 (m, 5H).

3.5.6

1H-Benzimidazole, 2-[(1S)-1-[[(1,1-dimethylethyl) dimethylsilyl]oxy]ethyl] (3-17)

A solution of (S)-1-)1H-Benzimidazol-2-yl) ethanol (100 mg, 0.617 mmol, 1 equiv.), imidazole (74 mg, 1.23
mmol, 2 equiv.), and tert-butyldimethylsilyl chloride (107mg, 0.709 mmol, 1.15 eq.) in DMF (3.1ml) was
stirred at room temperature for 50 minutes. After checking the TLC, the product was extracted with ethyl
acetate, then purified with silica gel chromotography using EtOAC: Hexane (30:70). Yield 94 mg (55%
yield). 1H NMR (400 MHz, CDCl3) δ 9.76 (s, 1H), 7.72 – 7.54 (m, 1H), 7.35 (d, J = 5.8 Hz, 1H), 7.15 (td, J =
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7.2, 6.2, 2.0 Hz, 2H), 5.15 (dd, J = 6.5, 1.0 Hz, 1H), 1.53 (dd, J = 6.5, 1.0 Hz, 3H), 0.85 (d, J = 1.1 Hz, 8H), 0.03
(dd, J = 22.0, 1.0 Hz, 5H).

3.5.7

Synthesis 6,7-dihydro-5H-pyrrolo[1,2-a] imidazole-7-ol (3-30)

According to the procedure from previously published by Zhenfeg zhang et al.130 A solution of imidazole
(0.1 g, 1.47 mmol, 1 equiv.), acrolein (0.147 ml, 2.203 mmol, 1.5 eq.) and acetic acid (58 µl, 0.1 mmol, 7
mol %) in dioxane (2.1 ml) was refluxed for 36 h at 101 °C. After monitoring the reaction by TLC, the solvent
was evaporated under reduced pressure. The crude product was purified by silica gel chromatography
using MeOH: CH2Cl2 (10:90) to provide 0.146 g (80% yield). The NMR data were matched for previously
publish results.130 The 1H NMR matched the published results. 1H NMR (400 MHz, CDCl3) δ 7.06 (dd, J =
4.4, 1.3 Hz, 1H), 6.83 (d, J = 1.3 Hz, 1H), 5.18 (ddd, J = 9.2, 7.3, 3.1 Hz, 1H), 4.29 – 3.79 (m, 2H), 2.99 – 2.38
(m, 2H).

3.5.8

Resolution of 6,7-dihydro-5H-pyrrolo[1,2-a] imidazole-7-ol (3-30)

A racemic solution of 6,7-dihydro-5H-pyrrolo[1,2-a] imidazole-7-ol, (81.6 mg, 6.58 mmol, 1 equiv.), Nov.
435 enzyme (81.6 mg, 1 equiv.) and isopropenyl acetate (3.79 ml, 32.22 mmol, 5 equiv.) in acetonitrile
(82.2 ml) was stirred for 7 h at 35 °C. After monitoring the reaction with TLC, the crude reaction was
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purified with silica gel column chromatography using MeOH/CH2Cl2 (10:90) to isolate the unreacted
starting material. Acetylated product 3-20 was obtained in 46% yield (52 mg). The NMR data were
matched for previously publish results.130 1H NMR (400 MHz, CDCl3) δ 7.19 (q, J = 1.3 Hz, 1H), 7.00 – 6.88
(m, 1H), 5.98 (dt, J = 7.2, 2.7 Hz, 1H), 4.25 – 3.85 (m, 2H), 3.15 – 2.43 (m, 2H), 2.13 – 1.98 (m, 4H).

3.5.9

Enantiomeric excess evolution from resolution

A solution of 6,7-dihydro-5H-pyrrolo[1,2-a] imidazole-7-acetate (3-20) (20 mg, 0.119 mmol, 1
equiv.) and K2CO3 (20 mg, 0.143 mmol, 1.2 equiv.) in CH3OH (1.2 ml) was stirred for 1h at room
temperature. After checking the TLC, the crude residue was analyzed with HPLC to determine the
enantiomeric excess (% ee).

3.5.10 Synthesis rac-formyl [2,2]paracyclophane (3-21)

A solution [2,2] paracyclophane (300 mg, 1.4402 mmol, 1 equiv.) in CH2Cl2 (10 ml) was prepared
and cooled to 0°C. Then, a solution of dichloromethyl methyl ether (173 mg, 1.05 mmol, 1.05 equiv.) and
1 M solution of titanium chloride (IV) (2.89 ml, 2.9 mmol, 2 equiv.) in CH2Cl2 (3 ml) was prepared. The
dichloromethyl methyl ether solution was added to the paracyclophane solution at 0°C. The mixture was
stirred for 6 hours at room temperature followed by water (10 ml) addition and stirred for 2 hours. After
the two phases formed, the aqueous phase was extracted with CH2Cl2 (10 ml) three times. The combined
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organic layers were dried over MgSO4 and concentrated under reduced pressure. The crude product was
purified by silica gel column chromatography using ethyl acetate: hexane (5:95) as eluent. Yield 26 mg
(76% yield) . The NMR data were matched for previously publish results. 132 1H NMR (500 MHz, CDCl3) δ
= 9.95 (s, 1H), 7.02 (d, J = 1.9 Hz, 1H), 6.73 (dd, J = 7.8 Hz, 1.9 Hz, 1H), 6.59 (d, J = 7.8 Hz, 1H), 6.56 (dd, J =
7.9 Hz, 1.8 Hz, 1H), 6.50 (dd, J = 7.9 Hz, 1.8 Hz, 1H), 6.43 (dd, J = 7.9 Hz, 1.8 Hz, 1H), 6.37 (dd, J = 7.9 Hz,
1.8 Hz, 1H), 4.10 (ddd, J = 11.8 Hz, 9.6 Hz, 1.5 Hz, 1H), 3.27 (ddd, J = 12.5 Hz, 10.4 Hz, 2.0 Hz, 1H), 3.21 (dd,
J = 11.7 Hz, 4.5 Hz, 1H), 3.18 (dd, J = 11.7 Hz, 4.5 Hz, 1H), 3.14-2.97 (m, 3H), 2.95 (ddd, J = 13.1 Hz, 10.1
Hz, 6.7 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ = 191.1, 143.2, 140.6, 139.5, 139.4, 138.1, 136.6, 136.3,
136.1, 133.2, 132.9, 132.3, 132.1, 35.2, 35.1, 35.0, 33.6.

3.5.11 Resolution of (3-21)

According to a previously published procedure,132 a mixture of racemic formyl
[2,2]paracyclophane 3-21) (500 mg, 2.116 mmol, 1 equiv.) and (-)-S-(phenyl) ethylamine (256 mg, 2.116
mmol, 1 equiv.) in toluene (14.1 ml) was stirred for 24 hours at 110 °C. A diastereomeric mixture of imine
moiety (3-22) was formed. After removing the toluene solvent by reducing pressure, the mixture was
dissolved again in n-hexane (10.6 ml). The diastereomeric mixture (3-22) was put in the fridge for 1 hour
until a white solid precipitate formed. Filtration and drying of the precipitate produced (S, R)-3-22 0.465
mg (22% yield) and 96% ee. Then, the compound (S, R)-(3-22) was dissolved in CH2Cl2 and filtered through
a silica column to give the enantiopure aldehyde moiety due to acidic properties of silica gel. The
enantiomeric enrichment of the aldehyde was confirmed by HPLC using chiral amylose-2 and an eluent of
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hexane/2-propanol (65:35) and 0.1 % of TFA, 0.5 ml /min, at 25°C. (S)-3-21 elutes at 6.5 minutes and (R)3-21 elutes at 7 minutes.

3.5.12 Synthesis nitrile-[2,2]paracyclophane (3-23)
To a 20 ml reaction vial was added formyl [2,2]paracyclophane (3-21) (171 mg, 0.724 mmol, 1
equiv.), sodium azide (235.5 mg, 3.622 mmol, 5 equiv.) and phosphorus oxychloride (1 ml, 10.87 mmol,
15 equiv.). The reaction mixture was stirred for 16 hours at 70 °C. Then, the reaction was quenched with
water and extracted with ethyl acetate (2 ml). The combined organic layers were dried over MgSO4 and
concentrated under reduced pressure. The crude product was purified by silica gel column
chromatography using ethyl acetate: hexane (10:90) as eluent to produce 128 mg (76% yield). 1H NMR
(400 MHz, CDCl3) δ 6.91 (dd, J = 8.1, 1.4 Hz, 2H), 6.77 – 6.70 (m, 2H), 6.62 – 6.45 (m, 6H), 5.30 (s, 1H), 3.64
– 3.40 (m, 9H), 3.30 (dddd, J = 12.8, 10.2, 4.5, 0.6 Hz, 2H), 3.21 – 2.97 (m, 11H), 1.91 – 1.79 (m, 4H), 1.78
– 1.63 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 148.9, 144.2, 140.9, 139.5, 139.1, 137.1, 136.7, 134.5, 133.5,
132.9, 132.7, 130.9, 77.3, 77.0, 76.7, 35.3, 35.1, 34.4, 34.2.

3.5.13 Synthesis 1H-tetrazle [2,2] paracyclophane (3-24)
To 20 ml, well-sealed vial was added the nitrile-[2,2]paracyclophane (3-23) (9.6 mg, 0.041 mmol,
1 equiv.), sodium azide (5.3 mg, 0.082 mmol, 2 equiv.), zinc bromide (18.4 mg, 0.0819 mmol, 2 equiv.),
and solution of 2:1 octanol: water (0.1 ml). The reaction mixture was vigorously stirred for 36 hours at
185 °C. After HPLC showed a partial formation of the product, the mixture was quenched with 3 N HCl
(0.3 ml) and extracted three times with ethyl acetate then dried with sodium sulfate. The product was
purified by silica gel chromatography with ethyl acetate: hexane (30:70) as eluent. Yield 1 mg (10%). 1H
NMR (500 MHz, CDCl3) δ 6.62 (dd, J = 7.8, 1.9 Hz, 1H), 6.56 – 6.50 (m, 3H), 6.43 (dd, J = 7.9, 1.5 Hz, 1H),
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3.78 (ddd, J = 12.8, 10.2, 2.4 Hz, 1H), 3.32 – 2.80 (m, 8H). 13C NMR (126 MHz, CDCl3) δ 140.3, 140.0, 139.9,
139.3, 136.3, 135.7, 132.8, 132.7, 132.6, 132.2, 131.9, 35.5, 35.4, 35.3, 35.1.

3.5.14 (rac)-4-Bromo[2,2]paracyclophane (3-25)

According to a previously published procedure132, a solution of bromine (0.11 ml, 2.1123 mmol,
1.1 equiv.) was prepared in CH2Cl2 (1.5 ml). A solution of iron powder (3.4 mg, 0.0609 mmol, 3 mol %) and
the bromine solution (0.3 ml) were mixed and stirred for 1 hour at room temperature. The reaction
mixture was diluted with CH2Cl2 (7 ml) and [2,2]paracyclophane (400 mg, 1.9203 mmol, 1 equiv.) was
added. The mixture was stirred for a further 20 min, followed by dropwise addition of the rest bromine
solution (1.2 ml) over 3 h. The reaction mixture was stirred for 16 h at room temperature. After confirming
the product by TLC, a saturated aqueous solution of Na2S2O3 was added. The aqueous phase was extracted
three time with CH2Cl2 (3 x 9 ml) and combined organic layers were dried over Na2SO4. The solvent was
removed under reduced pressure to give a white product 501 mg (91% yield). The NMR data matched
with a literature data.132 1H NMR (500 MHz, CDCl3) δ 7.17 (dd, J = 7.8, 2.0 Hz, 1H), 6.65 – 6.33 (m, 9H), 3.47
(ddd, J = 13.4, 10.2, 2.2 Hz, 1H), 3.30 – 2.70 (m, 10H).13C NMR (126 MHz, CDCl3) δ 141.6, 139.6, 139.3,
139.1, 137.3, 135.1, 133.3, 133.0 (d, J = 14.2 Hz), 132.3, 131.5, 128.7, 127.0, 35.9, 35.7, 35.5, 34.8, 33.5.
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3.5.15 [2,2]paracyclophayl-4-boronic acid pinacol ester (3-26)

To a 20 mL reaction vial under an atmosphere of N2 was prepared a solution of 4-bromo[2,2]paracyclophane (3-25) (0.5 g ,1.741 mmol, 1 equiv.) in THF (5.7 ml) . The solution was cooled to -78 °C followed by
dropwise addition of n-butyllithium solution (1.04 ml, 2.5M in hexane, 2.6114 mmol, 1.5 equiv.) and
stirred for 1 hour. A solution of bis(pinacolato)diboron (884 mg, 3.4818 mmol, 2 equiv.) in THF (3 ml) was
prepared. The solution of bis(pinacolato)diboron was added to the reaction mixture and left to stir for 1
hour at the same temperature. After the reaction temperature was left at room temperature, the reaction
was stirred for seven hours until the HPLC analysis confirmed the product 3-26. The reaction was
quenched with saturated ammonium chloride (9 ml) and extracted three times with ethyl acetate (3 x 10
ml). The combined organic layers were dried with MgSO4 and concentrated under reduced pressure. The
product 3-26 was purified with preparation HPLC using a C18 column as the stationary phase and
acetonitrile: water (35:65-95:5) as the eluent. Yield 145 mg (40%). The NMR data was matched the
literature.133 1H NMR (500 MHz, CDCl3) δ 7.04 (d, J = 1.9 Hz, 1H), 6.61 – 6.42 (m, 5H), 6.38 (dd, J = 7.7, 1.8
Hz, 1H), 3.96 (ddd, J = 12.6, 10.3, 2.1 Hz, 1H), 3.24 – 2.77 (m, 7H), 1.40 (d, J = 4.5 Hz, 12H). 13C NMR (126
MHz, CDCl3) δ 147.4, 140.3, 140.0, 139.6, 138.4, 135.3, 134.0, 133.2, 133.2, 132.6, 132.4, 83.2, 77.3, 77.0,
76.8, 35.9, 35.7, 35.6, 35.3, 25.1, 24.8.
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3.5.16 [2,2]paracyclophayl-4-boronic acid (3-27)

To a 20 mL reaction vial under an atmosphere of N2 was prepared a solution of 4-bromo [2,2]paracyclophane (3-25) (50 mg ,0.174 mmol, 1 equiv.) in THF (1.7 ml) . The solution was cooled to -78 °C followed by
dropwise addition of an n-butyl lithium solution (0.1155 ml, 2.5M in hexane, 0.296 mmol, 1.7 equiv.) and
stirred for 1 hour. Then, trimethyl borate (0.033 ml, 0.296 mmol, 1.7 equiv.) was added to the reaction
mixture and left to stir for 15 min. After the reaction temperature was at room temperature, the reaction
was stirred for another 1 hour until the HPLC analysis confirmed the product 3-27. The product 3-27 was
purified with preparative HPLC using a C18 column as the stationary phase and acetonitrile: water (35:6595:5) as the eluent. Yield 11 mg (25% yield ). 1H NMR (500 MHz, CDCl3) δ 7.01 (dd, J = 7.8, 1.8 Hz, 1H), 6.65
– 6.12 (m, 5H), 5.54 (s, 1H), 4.45 (s, 1H), 3.47 – 3.24 (m, 1H), 3.18 – 2.81 (m, 7H), 2.66 (dt, J = 13.6, 8.9 Hz,
1H). 13C NMR (126 MHz, CDCl3) δ 153.8, 142.13, 139.8, 139.0, 135.6, 133.7, 132.9, 132.0, 128.1, 125.6,
125.2, 122.7, 77.4, 77.2, 76.9, 35.4, 35.0, 34.0, 31.2, 1.2.

3.5.17 (S)-Methylbenzyl-1H-tetrazole (3-28)

To 20 ml reaction vial was added (S)-Methylbenzylamine (0.5319 ml, 4.1261 mmol, 1 equiv.) and
acetic acid (3 ml). Then, sodium azide (348 mg, 5.364 mmol, 1.3 equiv.) and triethylorthoformate (1 ml,
6.189 mmol, 1.5 equiv.) were added to the vial. The reaction mixture was stirred for 17 hours at 80 °C.
After HPLC analysis confirmed the product, the solvent was removed by reducing the pressure. The
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product was purified and isolated by preparative HPLC using a C18 column as the stationary phase and
acetonitrile: water (10:90-100:0.0) as the eluent. Yield 75% yield (539 mg). 1H NMR (500 MHz, CDCl3) δ
8.43 (s, 1H), 7.52 – 7.36 (m, 3H), 7.36 – 7.16 (m, 4H), 5.83 (q, J = 7.1 Hz, 1H), 2.05 (d, J = 7.1 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 141.7, 138.3, 129.5, 129.4, 126.8, 59.5, 21.5.

3.5.18 (S)-Methylbenzyl-5-bromo-1H-tetrazole (3-29)

To 20 ml vial was added a (S)-Methylbenzyl-1H-tetrazole (3-28) (0.7188 g, 4.1261 mmol, 1 equiv.), nbromosuccinimide (955 mg, 5.364 mmol, 1.3 equiv.), and acetic acid (4.13 ml). The solution was stirred
for 6 hours at 80 °C until HPLC analysis confirmed the product (3-29). The reaction was cooled to room
temperature and diluted with water (5 ml). The product was purified and by preparative HPLC using a C18
column as the stationary phase and acetonitrile: water (10:90-100:0.0) as the eluent. Yield 522 mg (50%
yield). 1H NMR (500 MHz, CDCl3) δ 7.45 – 7.13 (m, 1H), 5.71 (q, J = 7.1 Hz, 0H), 2.07 (d, J = 7.1 Hz, 1H). 13C
NMR (126 MHz, CDCl3) δ 138.0, 138.0, 132.7, 129.2, 129.0, 126.5, 59.7, 21.6.
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CHAPTER FOUR
4

4.1

QUANTITATIVE ANALYSIS OF PHOSPHORUS IN ENIROMENTAL SAMPLES BY 31P NUCLEAR
MAGNETIC RESONANCE SPECTROSCOPY
Introduction

Phosphorus is an essential nutrient for all organisms in the marine system and can be part of necessary
precursors for the biosynthesis of natural compounds.134,135 However, high P concentrations can
negatively affect the water quality by increasing the growth of nuisance algae, sedimentation, and
hypoxia.136,137 Therefore, controlling P concentration requires information about the various P chemical
forms available, which in turn determines the bioavailability and environmental reactivity.138,139
Marine sediment is the main source of phosphorus in water samples which accumulates through
biogeochemical processes.140 Mineralization of P to the sediment is another possible mechanism in which
P is released into the water.141 Additionally, the sedimentary P is also released due to the decomposition
of enzymes or bacterial that contain P in their cellular structure.141,142
The mechanism of inorganic P release into the sediment results from reductive dissolution of
phosphate complexed with Fe(III) hydroxides which is catalyzed through iron-reductive bacteria (IRB)
(Scheme 4.1).140,143 When the reduced Fe(II) reaches the oxic zones, either in the water or sediment layer,
it is re-oxidized to Fe(III) hydroxide and reabsorbed in the form of dissolved P onto the mineral surface.
The P bioavailability increases in the sediment when hydrogen sulfide (HS-) is present in the cycle due to
consumption of the reduced Fe (II) and transformation into iron sulfide (FeS). The presence of aluminum
hydroxides Al(OH)3 can inhibit dissolved P through binding under reduced conditions.143
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Scheme 4.1 Schematic diagram of inorganic phosphorus cycling in Maine lake sediment. Sulfatereducing bacteria (SRB) and iron-reducing bacteria (IRB) catalyze sedimentary P release. Fe(OH)3 and
Al(OH)3 represent the most abundant metal hydroxides.143
In a natural sample, phosphorus can be divided into inorganic P and organic P.139,143 P is considered
inorganic when it directly associates with metals in the form of orthophosphate, pyrophosphate, and
polyphosphate. Organic P contains carbon-hydrogen bonds in its constituent structure such as
orthophosphate monoesters, phosphate diesters, and organic polyphosphates. Orthophosphate
monoesters have a general structure, ROPO32-, in which R represents an organic motif per one
phosphorus. For example, the sugar glucose 6-phosphate or the hexahydroxy cyclohexane in phytic acid,
are orthophosphate monoesters as seen in Table 4.1 Entries 1 and 2.139,144
Orthophosphate diesters, with the general structure R1O(RO)PO2-, have two R groups for each one
phosphorus and include structures such as nucleic acids or phospholipids (Table 4.1 Entry 3). In
polyphosphates, the structure contains multiple monoester or diester groups such as adenosine
tripolyphosphate (ATP), as seen in Table 4.1 Entry 4. In phosphonates, phosphorus binds directly to carbon
with the general structure RP(O)(OH)2 , as can be seen in 2-aminoethyl phosphonic acid (AEP) (Table 4.1
Entry 5).144
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Table 4.1 Organic phosphorus classes in natural samples and their common structures 144
Functional class

Example compound

Structure

D-Glucose
Phosphate monoester 6-phosphate

Phosphate monoester Myo-Inositol
Hexakisphosphate
(phytic acid)

*Phosphate diester

L-α-Phosphatidyl
choline (lecithin)

Organic polyphosphate Adenosine
5’-triphosphate (ATP)

Phosphonate

2-Aminoethyl
phosphonic acid (AEP)
*

R: non identical hydrophobic fatty acyl chains

Since most analytical techniques are compound dependent, a useful characterization method for
determining sedimentary P level is a sequential fractionation method.139,145 However, this method is
laborious and time consuming, and depends on the solubility of the sample in various extractants. Also, it
cannot identify the organic or inorganic P species.139 NMR spectroscopy is well known as a powerful tool
for identifying molecular structures as well as the measurement of various chemical and physical
properties. The quantitative use of NMR has widely increased in the past decade 139,146–148.
Quantitative NMR has been used in environmental, agricultural, and pharmaceutical samples as
a promising approach for organic molecule quantification.138,149 Comparable to chromatographic
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methods, quantitative 31P NMR has high accuracy and precision with reliable results for pharmaceutical
and food samples.150 All P forms within environmental samples can be detected by NMR spectroscopy
because 31P is a ~100% naturally abundant isotope. Also, the area under the peak is proportional to the
number of P nuclei when using inverse gated decoupling and an appropriate relaxation time. However,
environmental samples need special treatment and extraction to avoid existing paramagnetic metals (Fe,
and Al) before preparing to quantitate

31

P NMR. Generally,

31

P NMR environmental samples contain

singlets between 25 and -25 ppm, as seen in Figure 4.1.138

Figure 4.1 The 31P NMR spectrum of forest floor sample after extraction with NaOH-EDTA shows diverse
P species, including organic P and inorganic P. PPE indicates terminal P in the polyphosphate chain.
Expanded orthophosphate monoesters region shows the peaks and structure of myo-inositol
hexakisphosphate (phytic acid). Reprinted from ref.122 with permission from Elsevier.138
For example, phosphonates appear at 20 ppm, orthophosphate at 5-7 ppm, orthophosphate
monoesters around 3-6 ppm, orthophosphate diesters at 2.5 to -1 ppm, pyrophosphate at -4 to -5 ppm
and polyphosphate at -20 ppm, respectively (Figure 4.1).138 Herein,

31

P NMR has been used for the

quantitative analysis of organic phosphorus in samples from Highland Lake, Maine. The samples have
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been subjected to several processes before running the

31

P NMR analysis, including pre- and post-

treatment, extraction, and redissolving samples. Additionally, acquisition parameters have been
optimized including delay time, proton decoupling, and experiment length in order to be as accurate as
possible.

4.2

4.2.1

Materials and Methods

The sediment extraction procedure
The extraction procedure used for the

31

P NMR study has previously been reported and was

conducted in collaboration with Aria Amirbahman.140 This technique can distinguish between organic P
(consisting of monoester and diester P), polyphosphates, and orthophosphate. Organic P and
polyphosphates together constitute biogenic phosphorus. Sediment phosphorus was extracted by shaking
approximately 10 g of wet sediment for 16 hr with 30 mL of 0.25 M NaOH/0.05 M EDTA. After
centrifugation, the supernatant was neutralized with 6 N HCl to a pH of 7-8 to preserve polyphosphates
during lyophilization.151 The supernatants were frozen at -80°C and placed in a freeze dryer until
completely dry. The dried samples were reconstituted in 3 mL of 1 M NaOH and centrifuged again. A 1 mL
aliquot was removed for total P analysis using a Perkin Elmer 3300XL inductively coupled with optical
emission spectrometer (ICP-OES) and another 1 mL aliquot transferred to an NMR tube. Deuterium oxide
(100 µL) was added to provide a lock signal and 100 µL of 0.1 M bicarbonate/dithionite solution was added
to reduce the remaining paramagnetic ions.

4.2.2

31

P NMR Acquisition Parameters

The samples were acquired on a Bruker 500 MHz NMR spectrometer equipped with a broadband
probe in 5 mm NMR tubes. The sample was locked and shimmed on the D2O present in the sample. For
quantitative NMR spectra, 31P NMR was taken after optimizing the 90° pulse width (P1) for each sample
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and using a delay time (d1) of 5.489 s, which is five times the measured relaxation time (5 x t1). The
relaxation time was measured for phosphate species by an inversion recovery experiment (t1= 1.0978 s).
The samples were scanned for approximately 11 hours and 19 minutes (~7,000 transients) with a spectral
window of 16,339.9 Hz, an acquisition time of 0.3 s, at 25 °C temperature, and a line-broadening of 10 Hz.
31

4.2.3

P NMR Processing

The resulting free induction decay (FID) data were processed using MestreNova 11 software. An
autophased and automated baseline correction for the FID data was carried out. Then, signal-to-noise
ratios (SNR) were measured between (88.6 to 325.07) for phosphate species. All expected peaks were
integrated and picked manually followed by calculation of the relative phosphorus abundances. The
difference between the orthophosphate concentration and total phosphorus is the organic phosphorus
concentration it was determined using ICP-OES.152 The concentration for each species can be calculated
by multiplying the relative abundance of the spectral peak by the total P concentration in the sample with
the assumption being that all P compounds were within the designated spectral window.140

4.3

Result and discussion
31

P NMR analysis for an environmental sample is more complex than purified samples due to the

low concentration of P species in environmental samples. Also, P species in nature are associated with
paramagnetic ions including iron (Fe) and manganese (Mn). Therefore, a pretreatment and extraction
with NaOH/EDTA lowers the concentration of paramagnetic ions and leads to accurate quantitative
results.153 The extraction process provides a high recovery of both organic and inorganic P.139
Environmental samples were collected from Highland Lake in Maine at various depths between 19-34 cm
in the middle of June to early July, 2019, due to the fact that the concentration of P increases in the lake
waters during the summer.140
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Quantitative 31P NMR required accurate determination of the spin-lattice relaxation times (T1) to
ensure an appropriate delay time between pulses. If T1 is insufficient, then the nuclei may not completely
relax to equilibrium. Therefore, the relative intensity of the peaks reduced compared with those which
are fully relaxed. Consequently, the integrated a peak area would not be comparable and would over- or
under-represent specific P species. Therefore, an inversion-recovery experiment was carried out to
measure T1 for orthophosphate in an environmental sample, which was found to be 1.0978 s. For
quantitative 31P NMR, a delay time (d1) five-times T1 was used as seen in Figure 4.2.

Figure 4.2 Diagram of measured relaxation times (T1).

The sediment depth has a strong influence on the P form because of the change in chemical and
physical properties. The total P was determined to be between 10-20 ppm using an inductively coupled
optical emission spectrometer (ICP-OES). The total P concentration is low on the surface and increases
with the sediment depth, as shown in Table 4.2 Entries 1-3 and Entries 4-6.
The P speciation in the sediments was determined by 31P NMR spectroscopy, as listed in Table 4.2
(spectra are shown in appendix F). The total organic P is a summation of phosphonate, orthophosphate
monoester, phosphodiester, pyrophosphate, and polyphosphate. While the detected orthophosphate
represents the inorganic phosphorus species, as seen in Table 4.2. The orthophosphate was determined
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as the highest P concentration in the samples (up to 0.4357 µmol g-1, 73%) due to the adsorption of
orthophosphate to Al(OH)3. The orthophosphate concentration was increased with sediment depth, as
seen in Table 4.2 Entries 1-3. The orthophosphate monoester was the second-highest abundance P species
found in the samples to reach up to 0.1387 µmol g-1 (25% ) (Table 4.2 Entries 1).
Table 4.2 P analysis of the samples collected from Highland Lake, Maine.
From 31P NMR Spectra
Entry Sediment Phosphonate OrthoP
OrthoP
Plipids Pdiesters PyroP
Total P
depth
(µmol g-1) (µmol g-1) Monoesters (µmol g-1) (µmol g-1) (µmol g-1)
(ppm)
(cm)
(µmol g-1)
(ICP-OES Analysis)
*12*3**4**5**6-

33.7
25.1
20.2
33.71
26.3
19

0.0148
0.0012
0.0046
5E-05
0.0002
0.0008

0.4357
0.2650
0.2332
0.4737
0.2172
0.2892

0.1387
0.1020
0.1186
0.1478
0.0873
0.1269

0.0007
0.0004
0.00003
0.00373
0.0017
0.0004

0.0108
0.0232
0.0104
0.0106
0.0161
0.0143

0.00142
0.00094
0.00051
5E-06
0.0017
0.00051

18.7
12.2
11.4
19.7
10.1
13.4

Phosphonate, Orthophosphate (Orthop), Phospho-lipids (Plipids), phosphodiester (Pdiesters), and
pyrophosphate (pyroP) concentrations were determined using 31P NMR at pH > 8 for solution. 31P
NMR were taken after optimization 90 pulse width (P1) and using a delay time (d1= 5.489 s) of 5xt1
where t1 measured for phosphate species (t1= 1.0978 s) by an inversion recovery array. The samples
were scanned 7000 times (11h 19 m) until the signal to noise was > 88.69.*measured at pH > 13.
** samples were collected for the similar sediment’s depth in middle of July 2019. ppm of P =
mg of P
kg of Total sample

mmol of P
x mmol of P
=
30.974 mg of P kg of Total Sample

x µmol of P

= g of Total Sample =

µmol
.
g

Phosphor diesters were detected up to 0.0108 µmol g-1 (1.8 %) and the majority of this species is
due to microbial DNA. Phosphonate, Phospholipid and pyrophosphate species were determined to be the
lowest P content in the samples (< 1%), as in Table 4.2. Samples were collected one month later in the
middle of July at a similar sediment depth (19-34 cm) and analyzed by 31P NMR as seen in Table 4.2 Entries
4-6. The total P concentration was similar for all samples compared to the samples taken in June (19-10
ppm), as seen in Table 4.2 entries 4-6. However, the P concentration at the middle depth (26.1 cm) was
the lowest concentration when compared with the highest or lowest depth samples as seen in Table 4.2
Entries 4-6.
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Due to the long experimental times, replicate 31P NMR acquisitions were not obtained. However,
to estimate the uncertainty associated with NMR processing, each acquisition was analyzed three times
to calculate a relative error (Table 4.3).
Table 4.3 Measurement uncertainties associated with samples using 31P NMR determined by replicate
processing of each of spectrum.
Entry

P contain range
(µmol g-1)

P fraction

Average
Mean

Average
Standard deviation

Average
relative error (%)

(µmol g-1)

1-

Phosphonate

0.00005 – 0.0148

0.027

0.006

21

2-

OrthoP

0.2172 – 0.4737

10.0

0.2

1

3-

0.0873 – 0.1478

5.8

0.15

3

4-

OrthoP
Monoesters
Plipids

0.00003 – 0.0037

0.29

0.06

18

5-

Pdiesters

0.0104 – 0.0232

0.69

0.004

2

6-

PyroP

0.00005 – 0.0017

0.14

0.003

14

Relative error (%) = (SD/mean) X 100
Uncertainty for each P species is listed in more detail in Table F.1. Phosphorus concentration
determinations contained uncertainties that ranged between 0.5% to 21% error (Table 4.3). The highest
uncertainty was found for phosphonate and phospholipid species due to the lowest signal compared to
other P species (up to 21% and 18.9 % respectively, as in Table 4.3 Entries 1 and 4). The uncertainty related
to measuring orthophosphate and orthophosphate monoester decreased to 1.38% and 3.22%
respectively due to the highest signal-to-noise ratio (Table 4.3 Entries 2 and 3). Finally, the uncertainty for
measuring phosphodiester and pyrophosphate was acceptable at 0.57% and 2.40% respectively, as seen
in Table 4.3 Entries 5 and 6.
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Figure 4.3 a) 31P NMR spectrum of sample 1 at 33.7 cm sedmint depth of Highland Lake in Maine after
NaOH/EDTA extracted at pH < 8. b) spectrum of the same sample at pH > 13. Spectra are ploted with 10Hz line broadening.
An important requirement for all NMR experiments is to obtain the spectra with a good resolution
and a high signal-to-noise ratio. In spectral resolution, the sharpness and separation of the peaks is
affected, while the signal-to-noise ratio describe the height of the peak relative to baseline noise. pH
samples can affect P speciation by influencing sample chemistry, organic matter decomposition, and the
extractability

of

P

compounds.

Lower

pH

favors

phosphonates,

orthophosphates,

and

phosphomonoesters which are correlated to the pH of the solution.138,139 Typically, 31P NMR experiments
are carried out at a pH < 8 to avoid P compound degradation. However, higher pH (pH > 13) is needed to
increase the peak separation and resolution. Therefore, the pH of some solutions were increased to > 13
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to obtain 31P NMR spectrum with high resolution and increase the p species separation. For example, the
spectrum resolution for sample 1 at 33.7 cm was increased with higher pH as seen in Figure 4.3.

4.4

Conclusion
Phosphorus nuclear magnetic resonance (31P NMR) spectroscopy is used for the quantitative

analysis of P forms in environmental samples. After pretreatment and extraction of the sediment in an
alkaline solvent (NaOH/EDTA), the

31

P NMR was acquired. A spin-lattice relaxation time (T1) for

orthophosphate was calculated to be 1.078 s to ensure adequate delay time between pulses. To increase
spectral resolution, the pH of the samples were adjusted to < 8 or > 13. The phophorus abundance was
determined for sediments at different depths from Highland Lake, Maine during the summer. The highest
abundance species were orthophosphate (up to 73%) and phosphomonoester (up to 25%). Other organic
species detected were phospholipids and phosphodiesters (up to 5%) and originate predominately form
microbial activity in the sediment. The remaining organic phosphorus species were detected in trace
quantities. Quantitative 31P NMR of dilute environmental samples was carried out to understand the origin
and variation of phosphorus species over depth and time.
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APPENDIX A: NMR Data for Chapter 2

Figure A.1 1H NMR of compound 2-13

Figure A.213C NMR of compound 2-13

100

Figure A.3 31P NMR of compound 2-13

Figure A.4 1H NMR of compound 2-35
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Figure A.5 13C NMR of compound 2-35

Figure A.6 31P NMR of compound 2-35
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Figure A.7 1H NMR of compound 2-40

Figure A.8 13C NMR of compound 2-40
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Figure A.9 31P NMR of compound 2-35

Figure A.10 1H NMR of compound 2-41
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Figure A.11 13C NMR of compound 2-41

Figure A.12 31P NMR of compound 2-41
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Figure A.13 1H NMR of compound 2-42

Figure A.14 13C NMR of compound 2-42
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Figure A.15 31P NMR of compound 2-42

Figure A.16 1H NMR of compound 2-43
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Figure A.17 13C NMR of compound 2-43

Figure A.18 31P NMR of compound 2-43
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Figure A.19 1H NMR of compound 2-15

Figure A.20 13C NMR of compound 2-15

109

Figure A.21 31P NMR of compound 2-15

Figure A.22 1H NMR of compound 2-24
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Figure A.23 13C NMR of compound 2-24

Figure A.24 31P NMR of compound 2-24
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Figure A.25 1H NMR of compound 2-25

Figure A.26 13C NMR of compound 2-25
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Figure A.27 31P NMR of compound 2-25

Figure A.28 1H NMR of compound 2-26
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Figure A.29 13C NMR of compound 2-26

Figure A.30 31P NMR of compound 2-26

114

Figure A.31 1H NMR of compound 2-27

Figure A.32 13C NMR of compound 2-27
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Figure A.33 31P NMR of compound 2-27

Figure A.34 1H NMR of compound 2-28
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Figure A.35 13C NMR of compound 2-28

Figure A.36 31P NMR of compound 2-28
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Figure A.37 1H NMR of compound 2-31

Figure A.38 13C NMR of compound 2-31
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Figure A.39 31P NMR of compound 2-31

Figure A.40 1H NMR of compound 2-32
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Figure A.41 13C NMR of compound 2-32

Figure A.42 31P NMR of compound 2-32
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Figure A.43 1H NMR of compound 2-33

Figure A.44 13C NMR of compound 2-33
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Figure A.45 31P NMR of compound 2-33

Figure A.46 1H NMR of compound 2-34
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Figure A.47 13C NMR of compound 2-34

Figure A.48 31P NMR of compound 2-34
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APPENDIX B: Mass spectra for Chapter 2

Figure B.1 Mass spectrum for compound 2-26

Figure B.2 Mass spectra for compound 2-27
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Figure B.3 Mass spectra for compound 2-28

Figure B.4 Mass spectra for compound 2-31
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Figure B.5 Mass spectrum for compound 2-32

Figure B.6 Mass spectra for compound 2-33
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APPENDIX C: HPLC Chromatograms for Chapter 2

Figure C.1 HPLC chromatogram of racemic mixture 2-15 synthesized without using catalyst (Amylose 2)

Figure C.2 HPLC chromatogram of compound 2-15 (Amylose 2)

Figure C.3 HPLC chromatogram of 2-24 using 10 mol % of (S)-2-16 (Amylose 2)
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Figure C.4 HPLC chromatogram of 2-25 using (S)-2-16 (Amylose 2)

Figure C.5 HPLC chromatogram of 2-26 using 10 mol % of (R)-2-16 (Amylose 2)

Figure C. HPLC chromatogram of 2-27 using 10 mol % of (S)-2-16 (Amylose 2)

Figure C.7 HPLC chromatogram of 2-28 using 10 mol % of (S)-2-16 (Amylose 2)
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Figure C.8 HPLC chromatogram of 2-31 using 10 mol % of (S)-2-16 (Amylose 2)

Figure C.9 HPLC chromatogram of 2-31 using 10 mol % of (R)-2-16 (Amylose 2)

Figure C.10 HPLC chromatogram of 2-32 using 10 mol % of (S)-2-16 (Amylose 2)

Figure C.11 HPLC chromatogram of 2-32 using 10 mol % of (R)-2-16 (Amylose 2)
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Figure C.12 HPLC chromatogram of racemic compound 2-33 without using (S)-2-16 (Cellulose 2)

Figure C.13 HPLC chromatogram of 2-33 using 10 mol % of (R)-2-16 (Cellulose 2)

Figure C.14 HPLC chromatogram of racemic compound 2-34 without using (S)-2-16 (Cellulose 2)

Figure C.15 HPLC chromatogram of 2-34 using 10 mol % of (S)-2-16 (Cellulose 2)
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APPENDIX D: NMR Data for Chapter 3

Figure D.1 1H NMR of compound 3-9

Figure D.2 31P NMR of compound 3-9
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Figure D.3 1H NMR of compound 3-11

Figure D.4 31P NMR of compound 3-11
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Figure D.5 1H NMR of compound 3-14

Figure D.6 31P- NMR of compound 3-14
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Figure D.7 1H NMR of compound 3-15

Figure D.8 31P- NMR of compound 3-15
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Figure D.9 1H NMR of compound 3-16

Figure D.10 1H NMR of compound 3-17
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Figure D.11 1H NMR of compound 3-30

Figure D.12 1H NMR of compound 3-20
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Figure D.13 1H NMR of compound 3-21

Figure D.14 13C-NMR of compound 3-21
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Figure D.15 1H NMR of compound 3-23

Figure D.16 13C-NMR of compound 3-23
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Figure D.17 1H NMR of compound 3-24

Figure D.18 13C-NMR of compound 3-24
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Figure D.19 1H NMR of compound 3-25

Figure D.20 13C-NMR of compound 3-25
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Figure D.21 1H NMR of compound 3-26

Figure D.22 13C-NMR of compound 3-26
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Figure D.23 1H NMR of compound 3-26

Figure D.24 13C-NMR of compound 3-27
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Figure D.25 1H NMR of compound 3-28

Figure D.26 13C-NMR of compound 3-28
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Figure D.27 1H NMR of compound 3-29

Figure D.28 13C-NMR of compound 3-29
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APPENDIX E: HPLC spectra for Chapter 3

Figure E.1 Analytical HPLC chromatogram of 3-15 using 5 mol % of (S)-3-16

Figure E.2 Analytical HPLC chromatogram of 3-15 using 5 mol % of (S)-3-18

Figure E.3 HPLC chromatogram of racemic compound 3-30
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Figure E.4 HPLC chromatogram of enantioenriched compound 3-30 after enzymatic resolution

Figure E.5 HPLC chromatogram of compound 3-24
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APPENDIX F: NMR Data for Chapter 4
Table F.1 Calculated relative error % for replicate integration of 31P NMR for samples.
Entry Phosphonate

OrthoP

OrthoP

Plipids

Pdiesters

PyroP

Monoesters
1-

11.024

1.308

0.004

15.712

5.8114

15.114

2-

37.796

1.373

3.181

0.191

0.525

1.878

3-

5.360

0.601

1.216

24.041

1.683

2.712

4-

42.183

4.465

17.816

33.038

3.18

24.713

5-

7.188

0.507

0.867

27.086

0.352

15.797

6-

19.61

0.074

0.328

7.163

0.651

25.932

Figure F.1 Representative 31P NMR spectra of the 0.25 M NaOH/0.05 M EDTA extracted surficial
sediment in 25.1 cm depth of Highland Lake until the pH of the solution is pH 7.
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Figure F.2 Representative 31P NMR spectrum of the 0.25 M NaOH/0.05 M EDTA extracted surficial
sediment in 20.2 cm depth of Highland Lake until the pH of the solution is pH 7.

Figure F.3 Representative 31P NMR spectrum of the 0.25 M NaOH/0.05 M EDTA extracted surficial
sediment in 20.2 cm depth of Highland Lake until the pH of the solution is pH 13.
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Figure F.4 Representative 31P NMR spectrum of the 0.25 M NaOH/0.05 M EDTA extracted surficial
sediment in 33.71 cm depth of Highland Lake until the pH of the solution is pH 7.

Figure F.5 Representative 31P NMR spectrum of the 0.25 M NaOH/0.05 M EDTA extracted surficial
sediment in 26.3 cm depth of Highland Lake until the pH of the solution is 7.
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Figure F.6 Representative 31P NMR spectrum of the 0.25 M NaOH/0.05 M EDTA extracted surficial
sediment in 19 cm depth of Highland Lake until the pH of the solution is 7.
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